<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003805.pub2" GROUP_ID="HAEMATOL" ID="096002031916212325" MERGED_FROM="" MODIFIED="2008-08-22 13:25:01 +0200" MODIFIED_BY="Nicole Skoetz" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2008-08-19 15:33:59 +0200" MODIFIED_BY="Nicole Skoetz">
<TITLE>Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma</TITLE>
<CONTACT>
<PERSON ID="DC971D3382E26AA200831C1987B75E16" MODIFIED="2008-08-19 15:33:35 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Holger</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schulz</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>hschulz@pioh.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 710770 19</PHONE_1>
<PHONE_2/>
<FAX_1>+49 221 710770 24</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-08-19 15:33:01 +0200" MODIFIED_BY="Nicole Skoetz">
<PERSON ID="DC971D3382E26AA200831C1987B75E16" MODIFIED="2008-08-19 15:32:37 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Holger</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schulz</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>hschulz@pioh.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 710770 19</PHONE_1>
<PHONE_2/>
<FAX_1>+49 221 710770 24</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19365" MODIFIED="2008-08-19 15:32:41 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Julia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bohlius</LAST_NAME>
<SUFFIX>MPH</SUFFIX>
<POSITION/>
<EMAIL_1>julia.bohlius@uk-koeln.de</EMAIL_1>
<EMAIL_2>jbohlius@ispm.unibe.ch</EMAIL_2>
<URL>www.chmg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 710770 25</PHONE_1>
<PHONE_2>+49 221 478 0</PHONE_2>
<FAX_1>+49 221 710770 24</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13787" MODIFIED="2008-08-19 15:32:43 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Nicole</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Skoetz</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>nicole.skoetz@uk-koeln.de</EMAIL_1>
<EMAIL_2/>
<URL>www.chmg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 710 770 21</PHONE_1>
<PHONE_2/>
<FAX_1>+49 221 710 770 24</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13792" MODIFIED="2008-08-19 15:32:47 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sven</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Trelle</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>strelle@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL>www.chmg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>CH-3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 6313328</PHONE_1>
<PHONE_2/>
<FAX_1>+41 31 6313520</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8623" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thilo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kober</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tk_smilingpressproductions@yahoo.com.au</EMAIL_1>
<EMAIL_2>Thilo.Kober@health.gov.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Smiling Press Productions</ORGANISATION>
<ADDRESS_1>3 Ulm Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Scullin</CITY>
<ZIP>ACT 2614</ZIP>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 (02) 62552838</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13778" MODIFIED="2008-08-19 15:32:52 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marcel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Reiser</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Registrar</POSITION>
<EMAIL_1>Marcel.Reiser@uni-koeln.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-221-478 ext: 3540</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="58FF01C082E26AA20003EB8A967453BB" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dreyling</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Martin.Dreyling@med.uni-muenchen.de &lt;Martin.Dreyling@med.uni-muenchen.de&gt;</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medizinische Klinik III</DEPARTMENT>
<ORGANISATION>Klinikum der Universität München-Großhadern</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81366</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>(089) 7095 2202</PHONE_1>
<PHONE_2/>
<FAX_1>(089) 7095 2201</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="58FEFF9D82E26AA20003EB8AC5C697DF" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Herold</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>miherold@klinikum-erfurt.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical Clinic Hematology/Oncology</DEPARTMENT>
<ORGANISATION>2. Medizinische Klinik, Helios Klinikum Erfurt</ORGANISATION>
<ADDRESS_1>Nordhäuser Straße 74</ADDRESS_1>
<ADDRESS_2/>
<CITY>Erfurt</CITY>
<ZIP>99089</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-(0)361 781 2478</PHONE_1>
<PHONE_2/>
<FAX_1>+49-(0)361 781 4803</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5936" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Guido</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schwarzer</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>sc@imbi.uni-freiburg.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Biometry and Statistics</DEPARTMENT>
<ORGANISATION>German Cochrane Center</ORGANISATION>
<ADDRESS_1>University Medical Center</ADDRESS_1>
<ADDRESS_2>Stefan-Meier-Str. 26</ADDRESS_2>
<CITY>Freiburg</CITY>
<ZIP>D-79104</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 761 203 6668</PHONE_1>
<PHONE_2/>
<FAX_1>+49 761 203 6680</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="22D8849982E26AA200CD32E57A6D26C7" MODIFIED="2008-08-19 15:32:57 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hallek</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Michael.hallek@uk-koeln.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0221 4780</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8933" MODIFIED="2008-08-19 15:33:01 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Andreas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Engert</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Senior Consultant</POSITION>
<EMAIL_1>a.engert@uni-koeln.de</EMAIL_1>
<EMAIL_2>baerbel.baecker@uk-koeln.de</EMAIL_2>
<URL>www.chmg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 478 5933</PHONE_1>
<PHONE_2>+49 221 478 5966</PHONE_2>
<FAX_1>+49 221 478 3778</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-08-19 15:14:14 +0200" MODIFIED_BY="Nicole Skoetz" NOTES="&lt;p&gt;Minor update: 7/31/07&lt;/p&gt;" NOTES_MODIFIED="2008-08-19 15:14:14 +0200" NOTES_MODIFIED_BY="Nicole Skoetz">
<UP_TO_DATE>
<DATE DAY="22" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="8" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="5" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="15" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-19 15:33:59 +0200" MODIFIED_BY="Nicole Skoetz"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Kompetence Network Malignant Lymphoma paid the salary for TK (1999-2001)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>The Editorial Base of CHMG is funded by the German Ministry of Education and Research (BMBF) FKZ : 01GH0501</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Editorial Base gets additional funding by &#8220;Köln Fortune&#8221; the funding programme from the medical faculty University of Cologne</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-19 16:48:09 +0200" MODIFIED_BY="Nicole Skoetz">
<SUMMARY>
<TITLE>Although the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy (R-chemo) has been shown to improve response rates and progression-free survival in patients with indolent or mantle cell lymphoma, the efficacy of R-chemo with respect to overall survival is unclear.</TITLE>
<SUMMARY_BODY>
<P>Study design: Meta-analysis of seven randomised controlled trials involving 1943 patients.<BR/>Contribution: Patients treated with R-chemo had better overall survival, overall response, complete response, and disease control but more leukocytopenia and fever than patients treated with chemotherapy alone. R-chemo improved overall survival in patients with follicular lymphoma. Implications: Concomitant treatment with rituximab and standard chemotherapy regimens should be considered the standard of care for patients with indolent and mantle cell lymphomas who require therapy and for patients with follicular lymphoma.<BR/>Limitations: Heterogeneity among the analysed mantle cell lymphoma trials precluded reliable assessment of efficacy of R-chemo with respect to overall survival. Variability in treatment regimens among trials precluded determination of which chemotherapy regimen is the best to combine with rituximab or about the optimal number of cycles needed to treat patients with indolent lymphoma. <BR/>Future directions: From our view future studies should focus on the following points:<BR/>1. Which standard chemotherapy should be used in combination with Rituximab<BR/>2. Influence of clinical and biologic prognostic markers after R-chemotherapy. What is similar and what is different<BR/>3. Understanding rituximab efficacy and resistance<BR/>4. Role of rituximab in treatment of progressive disease<BR/>5. Mechanism of rituximab in combination with chemotherapy<BR/>6. Role of Pharmacokinetic, pharmacogenetics in the treatment with R-chemo<BR/>7. Role of subsequent therapy with rituximab after R-chemo</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-19 15:34:40 +0200" MODIFIED_BY="Nicole Skoetz">
<ABS_BACKGROUND>
<P>Rituximab (R) has been shown to improve response rates and progression free survival when added to chemotherapy in patients with indolent and mantle cell lymphoma. However, the impact of R on overall survival (OS) when given in combination with chemotherapy (R-chemo) has remained unclear so far. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>We thus performed a comprehensive systematic review in this group of patients to compare R-chemo with chemotherapy alone with respect to OS. Other endpoints were overall response rate (ORR), toxicity and disease control as assessed by measures such as time to treatment failure (TTF), event free-survival (EFS), progression free-survival (PFS) and time to progression (TTP). </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE and conference proceeding from 1990 to 2005. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Only randomised controlled trials (RCT) comparing R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed indolent lymphoma and mantle cell lymphoma (MCL) were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-19 15:34:40 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Two review authors extracted data and assessed the study quality. Number needed to treat (NNT) were calculated to facilitate interpretation.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seven randomised controlled trials involving 1943 patients with follicular lymphoma, mantle cell lymphoma, or other indolent lymphomas were included in the meta-analysis. Five studies were published as full-text articles, and two were in abstract form. Patients treated with R-chemo had better overall survival (hazard ratio [HR] for mortality 0.65; 95% confidence interval (CI) 0.54 to 0.78), overall response (relative risk of tumour response 1.21; 95% CI 1.16 to 1.27), and disease control (HR of disease event 0.62; 95% CI 0.55 to 0.71) than patients treated with chemotherapy alone. R-chemo improved overall survival in patients with follicular lymphoma (HR for mortality 0.63; 95% CI 0.51 to 0.79) and in patients with mantle cell lymphoma (HR for mortality 0.60; 95% CI 0.37 to 0.98). However, in the latter case, there was heterogeneity among the trials (P 0.07), making the survival benefit less reliable. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The systematic review demonstrated improved OS for patients with indolent lymphoma, particularly in the subgroups of follicular and in mantle cell lymphoma when treated with R-chemo compared to chemotherapy alone.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-19 16:47:44 +0200" MODIFIED_BY="Nicole Skoetz">
<BACKGROUND>
<P>Non-Hodgkin lymphomas (NHL) are one of the leading causes of death from cancer in the United States and Europe and can be divided into aggressive (fast-growing) and indolent (slow-growing) types (<LINK REF="REF-Landis-1998" TYPE="REFERENCE">Landis 1998</LINK>). Patients with aggressive B-cell lymphoma are potentially curable using multi agent chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (<LINK REF="REF-Fisher-1993" TYPE="REFERENCE">Fisher 1993</LINK>). The standard of care has changed recently with the implementation of the chimeric anti-CD20 monoclonal antibody rituximab (R) (<LINK REF="REF-Boye-2003" TYPE="REFERENCE">Boye 2003</LINK>). Combination treatment of R and CHOP (R-CHOP) or similar regimen has resulted in superior treatment outcome and rendered R-CHOP as new standard in this group of patients (<LINK REF="REF-Feugier-2005" TYPE="REFERENCE">Feugier 2005</LINK>, <LINK REF="REF-Habermann-2005" TYPE="REFERENCE">Habermann 2005</LINK>).<BR/>The clinical course of indolent lymphoma, which make up 70% of non-Hodgkin lymphoma and the therapeutic approach differs from that of aggressive lymphoma. Prognosis and therapy for indolent lymphoma are closely related to the extent of the disease at initial diagnosis: less than 15% to 20% of patients with indolent lymphoma are diagnosed at an early stage of the disease (Ann Arbor stage I or II), and half of these patients experience long-term disease free survival after radiotherapy (<LINK REF="REF-Gallagher-1986" TYPE="REFERENCE">Gallagher 1986</LINK>). However, the vast majority of 80 patients with indolent lymphoma are diagnosed with advanced-stage disease (i.e., Ann Arbor stage III or IV) and cannot be cured with conventional therapy. These patients do not have a survival benefit from early treatment at diagnosis as compared with a watch-and-wait strategy, and it is generally accepted that treatment for such patients should be deferred until the disease becomes symptomatic (<LINK REF="REF-Ardeshna-2003" TYPE="REFERENCE">Ardeshna 2003</LINK>, <LINK REF="REF-Brice-1997" TYPE="REFERENCE">Brice 1997</LINK>, <LINK REF="REF-Barosi-2006" TYPE="REFERENCE">Barosi 2006</LINK>). For patients with symptomatic indolent lymphoma, a broad spectrum of therapeutic options are available, ranging from single agents to multi agent regimens or high-dose chemotherapy (<LINK REF="REF-McLaughlin-1986" TYPE="REFERENCE">McLaughlin 1986</LINK>, <LINK REF="REF-Zinzani-1998" TYPE="REFERENCE">Zinzani 1998</LINK>, <LINK REF="REF-Williams-2001" TYPE="REFERENCE">Williams 2001</LINK>).</P>
<P>The treatment course is typically characterized by a high initial response rates followed by regular relapse pattern with no or very few long-term survivors. Therefore, the prognosis of indolent lymphoma with a median survival of 8 to 10 years has changed very little over the last decades (<LINK REF="REF-Horning-1993" TYPE="REFERENCE">Horning 1993</LINK>). More recent survival data for patients with advanced indolent lymphoma suggest an improvement in OS over the last 25 years, probably because of sequential application of different chemotherapy regimens, incorporation of biologic agents and improved supportive care (<LINK REF="REF-Liu-2006" TYPE="REFERENCE">Liu 2006</LINK>, <LINK REF="REF-Swenson-2005" TYPE="REFERENCE">Swenson 2005</LINK>).</P>
<P>Mantle cell lymphoma (MCL) compromises approximately 3-10% of all NHL, which are often classified as an indolent lymphoma variant, because some patients with this disorder may survive untreated for many years. However, many patients with MCL have more aggressive disease, and for them the median overall survival is 3-5 years. Therefore therapy should be initiated at the time of diagnosis without deferral of treatment (<LINK REF="REF-Brody-2006" TYPE="REFERENCE">Brody 2006</LINK>). Currently, most investigators consider MCL to be an aggressive lymphoma, whereas in the past mantle cell lymphoma were mostly included in clinical trials with indolent lymphoma.<BR/> <BR/>Rituximab has shown impressive response and prolonged progression free survival (PFS) in patients with indolent and mantle cell lymphoma when combined with CHOP (<LINK REF="STD-Czuczman" TYPE="STUDY">Czuczman</LINK> 2004, <LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>). Randomised phase III trials adding rituximab to a variety of different regimens confirmed these benefits in previously treated as well as in untreated patients with advanced indolent lymphoma (<LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>, <LINK REF="STD-Marcus-2005" TYPE="STUDY">Marcus 2005</LINK>, <LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>, <LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>, <LINK REF="STD-Herold-2004" TYPE="STUDY">Herold 2004</LINK>). </P>
<P>Some of these trials (<LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>, <LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>, <LINK REF="STD-Herold-2004" TYPE="STUDY">Herold 2004</LINK>) have suggested a trend toward improved overall survival for patients treated with R-chemo, but the benefit was not definitive. We conducted a systematic review and meta-analysis of randomised controlled trials in which patients with advanced indolent lymphoma and mantle cell lymphoma were randomly assigned to receive R-chemo or chemotherapy alone. </P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this study was to examine the efficacy of combined immunochemotherapy using R-chemo compared with identical chemotherapy alone with respect to overall survival. Other endpoints included response rate, toxicity, and disease control as assessed by measures such as time to treatment failure, event-free survival, progression-free survival, and time to progression. The impact of maintenance therapy and sequential therapy with rituximab or other immunoconjugates was not addressed.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-19 16:03:21 +0200" MODIFIED_BY="Nicole Skoetz">
<SELECTION_CRITERIA MODIFIED="2008-08-19 15:55:34 +0200" MODIFIED_BY="Nicole Skoetz">
<CRIT_STUDIES>
<P>We included only randomised controlled trials (RCTs) that enrolled patients older than 18 years with histologically proven indolent lymphoma regardless of stage of disease or previous therapy. The studies were analysed if R-chemo was compared with identical chemotherapy alone. We included full-text, abstract publication and unpublished data. We excluded ongoing studies, interim analysis, quasi-randomised studies and studies with 10 or fewer patients per study arm. Studies on patients with human immunodeficiency virus (HIV) or with primary central nervous system lymphoma were excluded. As many studies do not provide information with regards to concealment of allocation (COA), a subgroup analysis is to be performed to compare treatment arms with a known COA with those with an unreported one.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-08-19 15:55:00 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Inclusion criteria:</P>
<P>1. All persons older 18 years with histologically proven indolent lymphoma and mantle cell lymphoma</P>
<P>Exclusion criteria:</P>
<OL>
<LI>Patients with Human Immunodeficiency Virus (HIV)</LI>
<LI>Patients with Hepatitis B or C</LI>
<LI>Patients with T-cell lymphoma</LI>
<LI>Patients with primary central nervous system lymphoma (PCNSL)</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Administration of combined chemotherapy with or without the monoclonal anti-CD20 antibody (Rituximab/Mabthera) to determine whether Rituximab improves disease control and overall survival (OS). For definitions of various clinical and technical terms see "Methods of Review" section. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-19 15:55:34 +0200" MODIFIED_BY="Nicole Skoetz">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-08-19 15:55:23 +0200" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>Overall survival (OS)</LI>
<LI>Disease control as assessed by time to treatment failure, event free-survival, progression free-survival and time to progression</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-08-19 15:55:30 +0200" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>Overall response rate (ORR)</LI>
<LI>Complete Response (CR) and Partial Response (PR)</LI>
<LI>Toxicity</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-19 16:03:06 +0200" MODIFIED_BY="Nicole Skoetz">
<ELECTRONIC_SEARCHES MODIFIED="2008-08-19 16:03:06 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Trials were identified by using comprehensive search strategies for identifying randomised controlled trials (RCT) as described by <LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>.</P>
<P>We searched a variety of electronic databases, such as the Cochrane Controlled Trials Register, MEDLINE, EMBASE, Lilac and Internet databases of ongoing clinical trials. The electronic databases were initially searched in April 2002 (period covered: from January 1990 through March 2002) and the search was updated in December 2005 (period covered: April 2002 through December 2005).</P>
<P>A preliminary search of specific electronic bibliographic databases to identify relevant RCTs was performed and will be regularly updated in the future. Trials identified thus far are listed in the "unpublished notes" section. </P>
<P>The Cochrane Library and MEDLINE (Silverplatter) were initially searched on 11.4.2002 (years 1990-2002) and updated in December 2005 using the following key words and truncations (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search strategy).<BR/>
</P>
<P>EMBASE was searched on 22.4.2002 through the German Institute for Medical Documentation and Information (DIMDI) using a search filter devised by the Scottish Intercollegiate Guideline Network (see http:www.sign.ac.uk/methodology/filters.html, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<P>LILAC was searched on 17.4.2002 by Ottavio Clark (Brazil) using the search strategy (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-08-19 15:59:28 +0200" MODIFIED_BY="Nicole Skoetz">
<P>
<B>Handsearching</B>
</P>
<P>We also hand searched the conference proceedings of </P>
<UL>
<LI>American Society of Hematology,</LI>
<LI>American Society of Clinical Oncology,</LI>
<LI>European Society of Medical Oncology</LI>
</UL>
<P>for clinical trials.</P>
<P>
<B>Contact</B>
</P>
<P>Investigators and pharmaceutical companies identified as active in the field were approached for unpublished data or studies. In addition, haemato-oncological study groups, such as </P>
<UL>
<LI>Eastern Cooperative Oncology Group (ECOG, South Western Oncology Group (SWOG),</LI>
<LI>National Cancer Institute (NCI),</LI>
<LI>European Organisation for the Treatment of Cancer (EORTC),</LI>
<LI>American Society of Hematology (ASH), </LI>
<LI>American Society of Clinical Oncology (ASCO)</LI>
</UL>
<P>were contacted.</P>
<P>Citations of all trials identified in the search were checked for additional references. No language restrictions were used. The full search strategy is published in the Cochrane library <LINK REF="REF-Kober-2002" TYPE="REFERENCE">Kober 2002</LINK>.</P>
<P>
<B>Databases of ongoing trials</B>
</P>
<P>Following databases were screened for the latest clinical investigations:</P>
<UL>
<LI>www.controlled-trials.com</LI>
<LI>http://www.doh.gov.uk/research/nrr.htm</LI>
<LI>http://clinicaltrials.nci.nih.gov</LI>
<LI>http://clinicaltrials.gov/ct/gui</LI>
<LI>www.eortc.be/</LI>
<LI>www.ctc.usyd.edu.au/</LI>
<LI>www.trialscentral.org/index.html</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-19 16:03:21 +0200" MODIFIED_BY="Nicole Skoetz">
<P>
<B>
<BR/>Trial selection<BR/>
</B>Two reviewers (H. Schulz and N. Skoetz) independently screened and screened for retrieval the titles and abstracts of all studies identified in the literature search to verify compliance with the inclusion and exclusion criteria. When this information was unsatisfactory, we performed a full-text analysis that considered the defined inclusion and exclusion criteria. Disagreements between the two reviewers were resolved by consensus involving a third reviewer (A. Engert). The same reviewers who screened the studies independently performed data extraction and quality assessment of all included articles. Assessment of the methodologic quality of clinical trials requires information about the design, conduct, and analysis of the trial (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>
<B>)</B>. All included studies, regardless of whether they are published or not, were assessed for internal validity parameters, with particular emphasis on randomisation, masking of patients and clinicians, concealment of allocation, documentation of dropout and withdrawals, and intent-to-treat analysis. We contacted the first authors of the included studies to obtain unreported data.</P>
<P>
<B>Data Analysis and Statistical Methods</B>
<BR/>A fixed effect model was assumed in all meta-analyses. For binary data, the relative risk (RR) was used as an indicator of treatment effect, and the Mantel-Haenszel Method was used for pooling. Overall survival and disease control were calculated as hazard ratios (HR) with data from published studies using methods described in <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK> or derived from binary mortality data. NNT for overall survival was calculated by assuming a 2-year overall survival of 90% for patients with follicular lymphoma and 70% for mantle cell lymphoma based on methods described by (<LINK REF="REF-Altman-1999" TYPE="REFERENCE">Altman 1999</LINK>). We used the -years survival, because the median follow up of the analysed studies ranged between 18 and 39 months. In meta-analyses with at least four trials a funnel plot was generated and a linear regression test <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) was performed to examine the likely presence of publication bias in meta-analysis. A P value less than 0.1 was considered statistically significant for the linear regression test.<BR/>Potential causes of heterogeneity were explored by performing sensitivity analyses to evaluate effects of lymphoma subtype, previous treatment, stage, duration of study, study quality, source of data, and the influence of single large studies on the effectiveness of rituximab treatment. Particular emphasis was made on the evaluation of additional toxicity of R-chemo in comparison to chemotherapy alone. Toxicity in context means any adverse event occurring during treatment. Toxicity was defined as any adverse events occurring during treatment including death.<BR/>Analyses were performed using Review Manager (RevMan, version 4.2.8 for Windows; Oxford, England): The Cochrane Collaboration 2004; the statistical software package R (<LINK REF="REF-Ihaka-1996" TYPE="REFERENCE">Ihaka 1996</LINK>) was used for additional analyses not possible with RevMan. Statistical tests for heterogeneity were one-sided; statistical tests for effect estimates and for publication bias were two-sided.</P>
<P>Sensitivity and subgroup analysis<BR/>Where sufficient data were available, sensitivity and subgroup analysis were performed based on the following characteristics.</P>
<P>Different qualities of studies, e.g. reporting of randomisation, blinding, concealment of allocation and attrition<BR/>
</P>
<UL>
<LI>different quality of studies</LI>
<LI>different size of studies</LI>
<LI>different source of studies (published sources vs. unpublished)</LI>
<LI>previous therapy</LI>
<LI>indolent lymphoma with the subgroup of follicular lymphoma or mantle cell lymphoma</LI>
</UL>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-19 16:46:15 +0200" MODIFIED_BY="Nicole Skoetz">
<STUDY_DESCRIPTION MODIFIED="2008-08-19 16:18:23 +0200" MODIFIED_BY="Nicole Skoetz">
<P>
<B>Trials identified</B>
<BR/>A total of 1345 potentially relevant trials describing treatment with rituximab were identified and screened for retrieval. 62 were evaluated in more detail. Of these, 55 were excluded for the following reasons: 33 articles were reviews, 2 articles described ongoing trials, 2 trials did not use identical chemotherapy in the control arm. 5 trials were non-randomised. In addition a total of 11 studies proved rituximab as monotherapy, maintenance therapy, consolidation therapy, in combination with radiotherapy, or as sequential treatment . These studies were excluded because they did not compare concurrent R-chemo as an induction therapy with identical chemotherapy alone.<BR/>Two trials evaluated the outcome of minimal residual disease, but not the endpoints such as overall survival or disease control.</P>
<P>
<B>Characteristics of studies analysed</B>
<BR/>A total of seven randomised controlled trials involving 1943 adult patients were thus included in the systematic review. In these trials 1480 patients had histologically proven FL and 260 patients had MCL. The remaining 203 patients were described as indolent lymphoma (N = 121), or lymphoplasmocytic/cytoid lymphoma or B-cell chronic lymphocytic leukaemia (N = 82) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).<BR/>Five trials included untreated patients with advanced disease (Ann Arbor III and IV, <LINK REF="REF-Rosenberg-1971" TYPE="REFERENCE">Rosenberg 1971</LINK>). The other two trials (<LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>, <LINK REF="STD-van-Oers-2006" TYPE="STUDY">van Oers 2006</LINK>) included relapsed or refractory patients with follicular or mantle cell histology. The chemotherapy regimens used included CHOP; cyclophosphamide, mitoxantrone, vincristine, and prednisone (CNOP); cyclophosphamide, vincristine, and prednisone (CVP); fludarabine, cyclophosphamide, and mitoxantrone (FCM); and mitoxantrone, chlorambucil, and prednisolone (MCP). All trials compared one of these regimens in combination with rituximab (indicated as R-chemo) with the chemotherapy regimen alone (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). In one trial (<LINK REF="STD-Rivas_x002d_Vera-2005" TYPE="STUDY">Rivas-Vera 2005</LINK>), patients were also randomly assigned to a third group to assess treatment with rituximab alone; those patients were not included in this meta-analysis. In two trials of R-CHOP versus CHOP, patients who were younger than 60 years (<LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>) or younger than 65 years (<LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>) and in remission were eligible for a second random assignment to adjuvant treatment with high-dose chemotherapy followed by either blood stem cell transplantation or interferon alpha maintenance; patients in remission who were 60 years or older (<LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>) or 65 years or older (<LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>) received interferon alpha maintenance. Two studies, one of the FCM regimen combined with rituximab versus FCM (<LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>) and the other of R-CHOP versus CHOP (<LINK REF="STD-van-Oers-2006" TYPE="STUDY">van Oers 2006</LINK>) offered patients in remission a second random assignment to either rituximab maintenance or observation. All the trials that offered a second random assignment showed a balanced distribution of the baseline characteristics of the patients included in the initial R-chemo and chemotherapy arms.</P>
<P>The following chemotherapeutic regimens were used:</P>
<UL>
<LI>CHOP cyclophosphamide (d1 750mg/m<SUP>2</SUP>), doxorubicin (d1 50mg/m<SUP>2</SUP>), vincristine (d1 1,4mg/m<SUP>2</SUP>), prednisone ( d1 to d5 100mg/m<SUP>2</SUP>) (<LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>, <LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>, <LINK REF="STD-van-Oers-2006" TYPE="STUDY">van Oers 2006</LINK>)</LI>
<LI>CNOP cyclophosphamide (d1 750mg/m<SUP>2</SUP>), mitoxantrone (d1 12mg/m<SUP>2</SUP>), vincristine (d1 1,2mg/m<SUP>2</SUP>) prednisone (d1 to d5 100mg) (<LINK REF="STD-Rivas_x002d_Vera-2005" TYPE="STUDY">Rivas-Vera 2005</LINK>)</LI>
<LI>CVP cyclophosphamide (d1 750mg/m<SUP>2</SUP>), vincristine (d1 1,4mg/m<SUP>2</SUP>), and prednisone (d1 to d5 40mg/m<SUP>2</SUP>) (<LINK REF="STD-Marcus-2005" TYPE="STUDY">Marcus 2005</LINK>)</LI>
<LI>FCM fludarabine (d1 to d3 25mg/m<SUP>2</SUP>), cyclophosphamide (d1 to d3 200mg/m<SUP>2</SUP>), mitoxantrone (d1 8mg/m<SUP>2</SUP>) (<LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>)</LI>
<LI>MCP mitoxantrone (d 3 and d4 8mg/m<SUP>2</SUP>), chlorambucil (d3 to d7 3 x 3mg/m<SUP>2</SUP> ), prednisolone (d3 to d7 25mg/m<SUP>2</SUP>) (<LINK REF="STD-Herold-2004" TYPE="STUDY">Herold 2004</LINK>)</LI>
</UL>
<P>All trials compared a combination of one of these regimens plus rituximab with chemotherapy alone. Rituximab was used in a dosage of 375mg/m<SUP>2</SUP> as a concurrent therapy with the combination chemotherapy either on day 1 or on the day before start of chemotherapy. There was one study who had an early failure design where patients were of study when they achieved only a stable disease after 4 cycles of R-chemo or chemo therapy (<LINK REF="STD-Marcus-2005" TYPE="STUDY">Marcus 2005</LINK>) .</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-19 16:09:04 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Details of the studies are shown in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. All studies were described as randomised and 6/7 trials had a clear and adequate allocation concealment. Most of the studies included intent to treat calculations (6/7) and only a few drop outs were described (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Only one study of <LINK REF="STD-Rivas_x002d_Vera-2005" TYPE="STUDY">Rivas-Vera 2005</LINK> were not described in detail and we were not able to receive further information according to allocation concealment and intention-to-treat-analysis. The single dosis of 375mg/m<SUP>2</SUP> used for rituximab was equal in all included studies. In exception of the study of <LINK REF="STD-Rivas_x002d_Vera-2005" TYPE="STUDY">Rivas-Vera 2005</LINK> were no information was provided, in all of the studies the two arms of comparison were well balanced. All of the studies were referred to as multicenter studies. Five of the studies were published as full text (<LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>;<LINK REF="STD-Herold-2004" TYPE="STUDY">Herold 2004</LINK>;<LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>;<LINK REF="STD-Marcus-2005" TYPE="STUDY">Marcus 2005</LINK>, <LINK REF="STD-van-Oers-2006" TYPE="STUDY">van Oers 2006</LINK>), and two were published in abstract form. For two of the six trials additional unpublished data were provided by the investigators. (<LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>;<LINK REF="STD-Herold-2004" TYPE="STUDY">Herold 2004</LINK>)</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-19 16:46:15 +0200" MODIFIED_BY="Nicole Skoetz">
<P>
<B>Overall Survival</B>
<BR/>Overall survival data were available for all 1943 patients included in the seven trials. The median observation time for all patients was 24 months (range = 18 to 39 months). There was no heterogeneity among trials (P = 0.62). On the basis of results reported by the individual studies, we calculated a pooled hazard ratio for death from any cause of 0.65 (95% CI = 0.54 to 0.78, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), indicating statistically significantly better overall survival in the R-chemo group compared with the chemotherapy-alone group. A sensitivity analysis revealed no evidence of a difference between the studies with respect whether the patients received previous treatment (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), the quality of the study (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), or whether the data were from published versus unpublished sources (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>A total of 1480 patients from five studies were included in our subgroup analysis of overall survival in follicular lymphoma. Of these patients, 759 were treated with R-chemo, of whom 97 died, and 721 were treated with chemotherapy alone, of whom 142 died. There was no heterogeneity among the trials (P = 0.59). The pooled hazard ratio for mortality for patients with follicular lymphoma was 0.63 (95% CI = 0.51 to 0.79, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), which indicates statistically significantly better overall survival in the R-chemo group than in chemotherapy-alone group. Assuming a 2-year overall survival rate of 90% for patients with follicular lymphoma and the estimated hazard ratio of 0.63, the number of patients who would need to be treated with R-chemo to prevent one additional death in 2 years was 28 (95% CI = 21 to 49.7).</P>
<P>For the subgroup analysis of patients with mantle cell lymphoma, we included three trials with a total of 260 patients. The calculated hazard ratio for death was 0.60 (95% CI = 0.37 to 0.98, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), which also indicated an advantage for the R-chemo group. However, there was heterogeneity among the trials (P = 0.07). In a sensitivity analysis that excluded the study by <LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>, which included patients who had relapsed and who had refractory disease, the heterogeneity disappeared (P = 0.54), but there was still an overall survival advantage for R-chemo compared with chemotherapy alone, with a pooled hazard ratio for mortality of 0.78 (95% CI = 0.45 to 1.35).</P>
<P>
<B>Disease Control</B>
<BR/>The seven trials included in the meta-analysis described different endpoints for treatment outcome, including event-free survival, time to treatment failure, progression-free survival, and time to progression. Documentation of resistance to initial therapy or death was available for 1913 patients. With respect to disease control, R-chemo was statistically significantly superior to chemotherapy alone, with a pooled HR of 0.62 (95% CI = 0.55 to 0.71, <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). This advantage was also seen in subgroup analyses comparing different defined intervals between the start of treatment and the documentation of death or progressive disease or between the end of treatment and the documentation of progressive disease or death (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). R-chemo was also statistically significantly superior to chemotherapy alone when subgroups of follicular lymphoma and mantle cell lymphoma were analysed (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
<P>
<B>Overall Response and Complete Response rates</B>
<BR/>The data for 1914 available patients were analysed for overall response. Among all patients with either indolent lymphoma or mantle cell lymphoma, 854 of 979 patients in the R-chemo group responded to treatment, compared with 673 of 935 patients in the chemotherapy alone group, corresponding to a relative risk of a response for R-chemo versus chemotherapy of 1.21 (95% CI = 1.16 to 1.27, <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). The rate of complete responses was statistically significantly higher in patients treated with R-chemo than in patients treated with chemotherapy alone (RR = 2.03; 95% CI = 1.71 to 2.40, <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>). In both analyses, there was heterogeneity among the trials (P &lt; 0.001). Subgroup analyses of follicular lymphoma patients and mantle cell lymphoma patients also revealed that the R-chemo arms had statistically significant higher overall response (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>) and complete response rates (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>) than the chemotherapy only arms.</P>
<P>
<B>Toxicity</B>
<BR/>We observed a lack of uniformity related to the reporting of treatment-associated side effects described between the seven selected trials. Three trials (<LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>, <LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>, <LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>) analysed toxicity over treatment cycles rather than recording absolute numbers of adverse events. Therefore, we could not include these three trials in the meta-analysis of side effects. We performed a meta-analysis of adverse events among the four trials that reported absolute numbers of adverse events (<LINK REF="STD-Marcus-2005" TYPE="STUDY">Marcus 2005</LINK>, <LINK REF="STD-van-Oers-2006" TYPE="STUDY">van Oers 2006</LINK>, <LINK REF="STD-Rivas_x002d_Vera-2005" TYPE="STUDY">Rivas-Vera 2005</LINK>, <LINK REF="STD-Herold-2004" TYPE="STUDY">Herold 2004</LINK>). Overall, toxicity was described as mild to moderate for both treatment groups. The most often reported grade 3 and 4 adverse events were hematotoxicity (i.e., leukocytopenia, thrombocytopenia, or granulocytopenia), fever, and infection. The relative risk for developing fever or leukocytopenia was statistically significantly higher in patients treated with R-chemo than in patients treated with chemotherapy alone (RR = 3.79; 95% confidence interval [CI] = 1.47 to 9.78 and RR = 1.31; 95% CI = 1.11 to 1.55, respectively, <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>). There was no evidence of a difference between treatment groups with respect to the risk of infection.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-19 16:47:22 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Four major results emerged from this systematic review and meta-analysis comparing R-chemo with chemotherapy alone in a total of 1943 patients with follicular lymphoma (N = 1480), mantle cell lymphoma (N = 260), and other indolent lymphomas (N = 203).</P>
<UL>
<LI>First, concurrent treatment with R-chemo improved overall survival in these patients compared with chemotherapy alone.</LI>
<LI>Second, patients treated with R-chemo had statistically significantly better overall response, complete response, and disease control than patients treated with chemotherapy alone.</LI>
<LI>Third, subgroup analyses revealed statistically significant and robust data for improved overall response, complete response, disease control, and overall survival in patients with follicular lymphoma; the data were less convincing for mantle cell lymphoma because of heterogeneity among the trials.</LI>
<LI>Fourth, patients treated with R-chemo had statistically significantly more leukocytopenia and fever than patients treated with chemotherapy alone, but there were no evidence of a difference in the frequencies of infections or thrombocytopenia between the groups.</LI>
</UL>
<P>To our knowledge, this comprehensive evaluation is the first meta-analysis to demonstrate that R-chemo improves overall survival in patients with advanced-stage indolent and mantle cell lymphomas compared with chemotherapy alone. There are two possible explanations for the survival advantage of R-chemo: patients treated with R-chemo may have higher initial response rates and/or prolonged disease control compared with patients treated with chemotherapy alone. The efficacy of rituximab as single-agent therapy was originally demonstrated in a pivotal study (<LINK REF="REF-McLaughlin-1998" TYPE="REFERENCE">McLaughlin 1998</LINK>) that included 166 patients with refractory or relapsed indolent B-cell non-Hodgkin lymphoma; the overall response rate was 48%. Early preclinical data suggested that rituximab potentiates the sensitivity of tumour cells to cytotoxic drugs (<LINK REF="REF-Demidem-1997" TYPE="REFERENCE">Demidem 1997</LINK>).</P>
<P>The antilymphoma activity of R-chemo reflects their different modes of action and the ability of the antibody to modify molecular signaling pathways. This latter effect is associated with decreased expression of the antiapoptotic gene products, Bcl-2 and Bcl-xL, and the sensitization of drug-resistant B-cell non-Hodgkin lymphoma cells to chemotherapy (<LINK REF="REF-Jazirehi-2005" TYPE="REFERENCE">Jazirehi 2005</LINK>, <LINK REF="REF-Jazirehi-2005a" TYPE="REFERENCE">Jazirehi 2005a</LINK>, <LINK REF="REF-Bonavida-2005" TYPE="REFERENCE">Bonavida 2005</LINK>). However, the contribution of these mechanisms to the cytoxicity of rituximab and the in vivo relevance of these pathways in patients with follicular or mantle cell lymphoma is unclear. One of the first multicenter phase II trials to use R-CHOP in patients with indolent lymphoma reported an overall response rate of 100% of all assessable patients and a complete response rate of 63% (<LINK REF="REF-Czuczman-1999" TYPE="REFERENCE">Czuczman 1999</LINK>). A recent update (<LINK REF="REF-Czuczman-2004" TYPE="REFERENCE">Czuczman 2004</LINK>) of this trial reported a median time to progression of 82.3 months and a duration of response of 83.5 months. In this trial, of eight patients who were Bcl-2 positive at baseline, seven became Bcl-2 negative, and three of the seven remained Bcl-2 negative and in ongoing remission at 85, 98, and 99 months. To date, the most comprehensive summary of prospective clinical trials evaluating R-chemo has been provided by the Hematology Disease Site Group (<LINK REF="REF-Imrie-2005" TYPE="REFERENCE">Imrie 2005</LINK>). Their systematic review, which included seven randomised controlled trials, suggested that R-chemo should be used in previously untreated and treated patients with follicular or other indolent B-cell non-Hodgkin lymphomas.</P>
<P>This recommendation was based on the balance between the risks of toxicity associated with rituximab and the benefits of delaying recurrent disease and the toxicity associated with re-treatment. However, the trials included in that systematic review did not show statistically significant improved overall survival for patients with follicular and other indolent lymphomas, and a meta-analysis was not performed. Our study has several limitations. First, the studies included in this analysis offered a variety of chemotherapy regimens, such as CHOP, CNOP, FCM, CVP, and MCP. The number of cycles scheduled applied ranged from four to eight, depending on the application of additional consolidation treatment. Options ranged from no adjuvant treatment to high-dose chemotherapy and stem cell transplantation. Therefore, with the currently available data, we cannot comment about which chemotherapy regimen is the best to combine with rituximab or about the optimal number of cycles needed to treat patients with indolent lymphoma. Second, although two trials (<LINK REF="STD-Marcus-2005" TYPE="STUDY">Marcus 2005</LINK>, <LINK REF="STD-Hiddemann-2005" TYPE="STUDY">Hiddemann 2005</LINK>) included in this analysis showed that the addition of rituximab to chemotherapy reduced the risk of disease progression in both low- and high-risk patients, the data were insufficient to perform subgroup analyses on the basis of prognostic scores and biologic parameters (<LINK REF="REF-Solal_x002d_Celigny-2004" TYPE="REFERENCE">Solal-Celigny 2004</LINK>, <LINK REF="REF-Montoto-2003" TYPE="REFERENCE">Montoto 2003</LINK>). Third, only three randomised controlled studies (<LINK REF="STD-Lenz-2005" TYPE="STUDY">Lenz 2005</LINK>, <LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>, <LINK REF="STD-Herold-2004" TYPE="STUDY">Herold 2004</LINK>) included patients with mantle cell lymphoma. Although we found that mantle cell lymphoma patients who were treated with R-chemo had better overall survival, disease control, and overall response than patients treated with chemotherapy alone, the evidence for improved overall survival was less reliable than that for patients with follicular lymphoma because of the statistically significant heterogeneity among the analysed mantle cell lymphoma trials. This heterogeneity was caused mainly by the study of <LINK REF="STD-Forstpointner-2004" TYPE="STUDY">Forstpointner 2004</LINK>, which included relapsed or refractory patients with mantle cell lymphoma, whereas the two other studies enrolled untreated patients only. There is a clear need for more prospective randomised trials in patients with advanced indolent lymphoma, with separated and adequately powered trials for untreated patients and patients with relapsed or refractory mantle cell lymphoma. These trials should focus on the impact of rituximab in different risk groups and on the intensity of chemotherapy needed for favourable low-risk patients, as is the ongoing PRIMA study from the Group d'Etudes de Lymphomes de L'Adulte, which is evaluating the role of maintenance rituximab in first-line therapy. The impact of maintenance treatment with rituximab on overall survival, which was not evaluated in this analysis, is one of the most important open questions for patients with indolent non-Hodgkin lymphoma. Recent randomised trials performed by the German Low Grade Lymphoma Study Group (GLSG) and by the EORTC demonstrated the superiority of rituximab maintenance after immunochemotherapy (<LINK REF="STD-van-Oers-2006" TYPE="STUDY">van Oers 2006</LINK>, <LINK REF="REF-Dreyling-2006" TYPE="REFERENCE">Dreyling 2006</LINK>) and after chemotherapy (<LINK REF="STD-van-Oers-2006" TYPE="STUDY">van Oers 2006</LINK>) compared with observation alone. However, the present review analysed trials conducted at a time of the rituximab era, when rituximab use was restricted to patients with relapsed disease. Therefore, the difference in overall survival between patients treated initially with immunochemotherapy or chemotherapy alone followed by maintenance therapy with rituximab might be smaller in current and future practice. There is also a need for additional randomised controlled trials in patients with mantle cell lymphoma to test the addition of rituximab to more intense chemotherapy regimens, such as dexamethasone, high-dose cytarabine, and cisplatin or hyperfractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone followed by stem cell transplantation, or rituximab in combination with other new treatment drugs. In conclusion, this meta-analysis demonstrated that, in patients with indolent or mantle cell lymphoma, R-chemo is superior to chemotherapy alone with respect to remission induction, progression-free survival, and overall survival. Therefore, concomitant treatment with rituximab and standard chemotherapy regimens should be considered the standard of care for patients with indolent and mantle cell lymphomas who require therapy and for patients with follicular lymphoma.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-19 16:47:44 +0200" MODIFIED_BY="Nicole Skoetz">
<IMPLICATIONS_PRACTICE>
<P>This systematic review and meta-analysis specifically focus on clinically relevant endpoints such as event free survival and overall survival. We think that this manuscript is timely and relevant to the reader in this field since it adds important information to the ongoing discussion on the impact of rituximab on overall survival in patients with indolent lymphoma and mantle cell lymphoma. Our data demonstrate that combined immunochemotherapy significantly improves overall survival in patients with indolent lymphoma compared to chemotherapy alone. Thus we conclude that concomitant application of rituximab with standard chemotherapy regimen should be considered standard in patients with indolent lymphoma requiring therapy. From our view these results could lead to a major change in the treatment strategies of patients with indolent lymphoma.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-19 16:47:44 +0200" MODIFIED_BY="Nicole Skoetz">
<P>With this review there is evidence for improved survival for concomitant application of rituximab to a standard chemotherapy regimen in patients with indolent lymphoma.<BR/>From our view future studies should focus on the following points:</P>
<OL>
<LI>Which standard chemotherapy should be used in combination with Rituximab</LI>
<LI>Influence of clinical and biologic prognostic markers after R-chemotherapy. What is similar and what is different</LI>
<LI>Understanding rituximab efficacy and resistance</LI>
<LI>Role of rituximab in treatment of progressive disease</LI>
<LI>Mechanism of rituximab in combination with chemotherapy</LI>
<LI>Role of Pharmacokinetic, pharmacogenomics in the treatment with R-chemo</LI>
<LI>Role of subsequent therapy with rituximab after R-chemo</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank all authors and investigators who provided us with additional information. We thank the editors of and the consumers of the Cochrane Hematological Malignancies Group for strong support. <BR/>The CHMG is funded by the German Ministry of Education and Research (BMBF), Grant application No.: 01GH501 and gets additional funding by "Köln Fortune" the funding programme from the medical faculty University of Cologne.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Thilo Kober was up to March 2006 the co-ordinator of the Cochrane Haematological Malignancies Group (CHMG) and was involved in the preparation of systematic reviews and other material for the Cochrane Library. Julia Bohlius is a medical officer and reviewer, Andreas Engert is the CHMG co-ordinating editor and Holger Schulz is a medical officer and reviewer in the CHMG editorial base. <BR/>All are or were involved in the preparation of systematic reviews. This protocol is not supported by the pharmaceutical industry or by any grant.<BR/>J. Bohlius gave two presentations on erythropoiesis-stimulating agents at Hoffmann-La Roche &amp; Co, the manufacturer of rituximab.<BR/>M. Reiser, M. Herold, M. Dreyling, and M. Hallek have conducted research sponsored by Hoffmann-La Roche &amp; Co, the manufacturer of rituximab. M. Herold is a member of the Hoffmann-La Roche &amp; Co Speaker's bureau, and M. Dreyling has received a speaker's honorarium from Hoffmann-La Roche &amp; Co. M. Herold is a member of the Hoffmann-La Roche &amp; Co advisory board.<BR/>.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-19 16:48:09 +0200" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>Holger Schulz: Conception and design, provision of study material, data extraction, analysis and interpretation, writing of review and final approval.</LI>
<LI>Thilo Kober: Protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis, drafting and writing of final review</LI>
<LI>Julia Bohlius: Methodological advice, conception and design, provision of study material, data extraction, analysis and interpretation, writing of review and final approval.</LI>
<LI>Andreas Engert: Clinical and scientific advice, conception and design, analysis and interpretation of data, writing of review and final approval.</LI>
<LI>Marcel Reiser: Conception and design, analysis and interpretation, writing of review and final approval.</LI>
<LI>Nicole Skoetz: Conception and design, provision of study material, data extraction, analysis and interpretation, writing of review and final approval.</LI>
<LI>Martin Dreyling: provision of study material, data extraction, writing of review and final approval.</LI>
<LI>Michael Herold: provision of study material, writing of review and final approval.</LI>
<LI>Sven Trelle: Conception and design, methodological advice, data extraction, analysis and interpretation, writing of review and final approval.</LI>
<LI>Guido Schwarzer: Methodological advice, data analysis and interpretation, writing of review and final approval.</LI>
<LI>Michael Hallek: Clinical and scientific advice, writing of review and final approval.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Forstpointner-2004" NAME="Forstpointner 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al.</AU>
<TI>The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>10</NO>
<PG>3064-3071</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Herold-2004" NAME="Herold 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, et al</AU>
<TI>Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL)</TI>
<SO>ASH Annual Meeting Abstracts</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>11</NO>
<PG>584</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiddemann-2005" NAME="Hiddemann 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al.</AU>
<TI>Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>12</NO>
<PG>3725-3732</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenz-2005" NAME="Lenz 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al</AU>
<TI>Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)</TI>
<SO>J Clin Oncol</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1984-1992</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcus-2005" NAME="Marcus 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al</AU>
<TI>CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>4</NO>
<PG>1417-1423</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rivas_x002d_Vera-2005" NAME="Rivas-Vera 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rivas-Vera S, Baez E, Sobrevilla-Calvo P, Baltazar S, Tripp F, Vela J,et al</AU>
<TI>Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin's Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP</TI>
<SO>ASH Annual Meeting Abstracts</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>11</NO>
<PG>2431</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Oers-2006" NAME="van Oers 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A.</AU>
<TI>Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108 (10)</VL>
<PG>3295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Byrd-JC" NAME="Byrd JC" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byrd JC, Peterson BL, Morrison VA et al.</AU>
<TI>Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>101</VL>
<PG>6-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2002" NAME="Cohen 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen et al.</AU>
<TI>Results of a phase II study employing a combination of Fludarabine, Cyclophosphamide and Rituximab (FCR) as a primary therapy for patiens with advanced follicular lymphoma (FL): the israel cooperative group</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100, No 11</VL>
<PG>abstract 1393</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czuczman" NAME="Czuczman" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH.</AU>
<TI>Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.</TI>
<SO>J Clin Oncol. 2005 Feb 1;23(4):694-704</SO>
<YR>2005</YR>
<VL>Feb 1; 23 (4)</VL>
<PG>694-704</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czuczman-M" NAME="Czuczman M" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ.</AU>
<TI>Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.</TI>
<SO>J Clin Oncol</SO>
<YR>2004</YR>
<VL>Dec 1; 22 (23)</VL>
<PG>4711-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doelken-G" NAME="Doelken G" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doelken G, Schueler F, Kiefer T, Herold M, Hirt C</AU>
<TI>Rapid clearance of circulating lymphoma cells from peripheral blood of follicular lymphoma patients treated with chemotherapy and rituximab as compared to patients treated with chemotherapy alone</TI>
<SO>Hematology</SO>
<YR>2002</YR>
<VL>3 Suppl. 1</VL>
<PG>278</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghielmeni-M" NAME="Ghielmeni M" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny</AU>
<TI>Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>103 (12)</VL>
<PG>4416-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gregory-S" NAME="Gregory S" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gregory SA</AU>
<TI>A phase II study of ludarabine and mitoxantrone followed by anti-CD 20 monoclonal antibody in the treatment of patients with newly diagnosed, advanced low grade non Hodgkin´s lymphoma (LGNHL): interim results</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102, 11, Part 1, 412a</VL>
<PG>abstract 1499</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hainsworth-J" NAME="Hainsworth J" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA.</AU>
<TI>Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.</TI>
<SO>J Clin Oncol</SO>
<YR>2005</YR>
<VL>23 (6)</VL>
<PG>1088-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hochster-H" NAME="Hochster H" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>H. S. Hochster, E. Weller, T. Ryan, T. M. Habermann, R. Gascoyne, S. R. Frankel and S. J. Horning</AU>
<TI>Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)</TI>
<SO>ASCO Annual Meeting Proceedings (Post-Meeting Edition). abstract 6502 Vol 22, No 14S (July 15 Supplement), 2004: 6502</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-J" NAME="Huang J" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jane E. Huang, Lowell Hart, Jonathon Polikoff, Virginia Langmuir, Fan Zhang, and Louis Fehrenbacher</AU>
<TI>Rituximab Plus CHOP Followed by Maintenance Rituximab as Initial Therapy for Advanced Stage Indolent Non-Hodgkin&#8217;s Lymphoma (NHL); Initial Results of Induction Therapy in a Phase II Study.</TI>
<SO>Blood (ASH Annual Meeting Abstracts), abstract: 4615.</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-Y" NAME="Jiang Y" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yunfang Jiang, Peter McLaughlin, Athanasios Thomaides, David Simons, Ajay Sehgal, Thomas Sneed, Ofelia Mesina, Marilyn Clemons, Ana Ayals, Georgios Z. Rassidakis, L. Jeffrey Mederios, Andreas H. Sarris, Frederic Gilles, Fernando Cabanillas, Andre Goy</AU>
<TI>Quantification and Monitoring of the t(14;18) Translocation Copy Number by Real-Time PCR in Patients with Follicular Lymphoma Treated with FND Plus Concurrent or Delayed Rituximab</TI>
<SO>Amercian Society of Hematology : abstract 1444</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katakkar-S" NAME="Katakkar S" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Suresh B. Katakkar,</AU>
<TI>A Combination of Rituximab with Chemotherapy in Low Grade Lymphoma</TI>
<SO>Blood (ASH Annual Meeting Abstracts) abstract 4647</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meckenstock-G" NAME="Meckenstock G" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>G. Meckenstock, S. Martin, G. Kobbe, P. Möller, M. Bentz, C. Aul, A. Raghavachar, A. Wehmeier, D. Braumann, C. Losem, A. Nusch, R. Kronenwett, H. Döhner, R. Haas</AU>
<TI>Firstline treatment of advanced follicular lymphoma comparing fludarabine/Mitoxantrone and high-dose chemotherapy, each combined with CD20-antibody rituximab</TI>
<SO>Onkologie; abstract 869</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettengell" NAME="Pettengell" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Pettengell R, Linch DC</AU>
<TI>Phase III Randomized Study of Rituximab Purging and Maintenance With Perupheral Blood Stem Cell Transplantation in Patients With Relapsed or Resistant Follicular Non-Hodgkin's Lymphoma Undergoing High-Dose Chemotherapy</TI>
<SO>Ongoing Clinical Trial</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Ref.: 14674"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rambaldi-A" NAME="Rambaldi A" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rambaldi A</AU>
<TI>Long term improvement of clinical outcomes of follicular lymphoma patients achieving a molecular response after sequential CHOP and rituximab treatment: predictive value of real time quantitative PCR to identify responding patients</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102, No 11, Part 1, 409a</VL>
<PG>abstract 1487</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rule-S" NAME="Rule S" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Rule S, Seymour J</AU>
<TI>Phase II Randomized Study of Fludarabine and Cyclophopshamide With or Without Rituximab inPatients With Previously Untreated Mantle Cell Lymphoma</TI>
<SO>Ongoing Trial</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Ref: 14665"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salles-G" NAME="Salles G" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gilles Andre Salles, Charles Foussard, Mounier Nicolas, Morschhauser Franck, Doyen Chantal, Lamy Thierry, Haioun Corinne, Brice Pauline, Bouabdallah Reda, Rossi Jean-François, Audhuy Bruno, Fermé Christophe, Mahe Béatrice, Feugier Pierre, Sebban Catherine, Colombat Philippe, and Xerri Luc</AU>
<TI>Rituximab Added {alpha}IFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients.</TI>
<SO>ASH Annual Meeting Abstracts</SO>
<YR>2004</YR>
<VL>104</VL>
<PG>160</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solal_x002d_Celigny-P" NAME="Solal-Celigny P" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Philippe Solal-Celigny, Gilles Andre Salles, Nicole Brousse, Patricia Franchi-Rezgui, Pierre Soubeyran, Vincent Delwail, Eric Deconinck, Corinne Haioun, Charles Foussard, Catherine Sebban, Herve Tilly, Noel-Jean Milpied, Francois Boue, Jean-Michel Karsenti, Pierre Lederlin, Albert Najman, Catherine Thieblemont, Franck Morschhauser, Nathalie Berriot-Varoqueaux, Loic Bergougnoux, and Philippe Colombat</AU>
<TI>Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.</TI>
<SO>ASH Annual Meeting Abstracts 585</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tobinai" NAME="Tobinai" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogura,M.; Morishima,Y.; Kagami,Y.; Watanabe,T.; Itoh,K.; Igarashi,T.; Hotta,T.; Kinoshita,T.; Ohashi,Y.; Mori,S.; Terauchi,T.; Tobinai,K.</AU>
<TI>Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma</TI>
<SO>Cancer Sci.</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>4</NO>
<PG>305-312</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vitolo" NAME="Vitolo" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vitolo U et al.</AU>
<TI>A brief course of chemo-immunotherapy FND + rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis"</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102, 11, Part1, 400a</VL>
<PG>abstract 1452</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witzig" NAME="Witzig" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witzig,T.E.; Vukov,A.M.; Habermann,T.M.; Geyer,S.; Kurtin,P.J.; Friedenberg,W.R., et al.</AU>
<TI>Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1103-1108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zinzani-PL" NAME="Zinzani PL" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zinzani PL, Pulsoni A, Perrotti A et al.</AU>
<TI>Fludarabine plus mitoxantrone with and without rituximab vs as front-line treatment for patients with follicular lymphoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>2654-2661</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-GELA-Study" NAME="GELA Study" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Groupe d&#8217;Etudes de Lymphomes de L&#8217;Adulte HOVON&#8212;Dutch Haemato-Oncology Association German Low Grade Lymphoma Study Group OSHO Australasian Leukaemia and Lymphoma Group (ALLG) Institute of Cancer Research, United Kingdom. Advanced</AU>
<TI>Advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (MabThera) after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy. Ongoing clinical trial</TI>
<SO>Available at: clinicaltrials.gov NCT00140582</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sonneveld" NAME="Sonneveld" YEAR="">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Altman-1999" NAME="Altman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Andersen PK</AU>
<TI>Calculating the number needed to treat for trials where the outcome is time to an event</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<NO>7223</NO>
<PG>1492-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ardeshna-2003" NAME="Ardeshna 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al.</AU>
<TI>Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9383</NO>
<PG>516-522</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barosi-2006" NAME="Barosi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, et al.</AU>
<TI>Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation</TI>
<SO>Haematologica</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>1</NO>
<PG>96-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonavida-2005" NAME="Bonavida 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bonavida B, Vega MI</AU>
<TI>Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma</TI>
<SO>Drug Resist Updat</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>1-2</NO>
<PG>27-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boye-2003" NAME="Boye 2003" TYPE="JOURNAL_ARTICLE">
<AU>Boye J, Elter T, Engert A</AU>
<TI>An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>4</NO>
<PG>520-535</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brice-1997" NAME="Brice 1997" TYPE="JOURNAL_ARTICLE">
<AU>Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al.</AU>
<TI>Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>3</NO>
<PG>1110-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brody-2006" NAME="Brody 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brody J, Advani R.</AU>
<TI>Treatment of mantle cell lymphoma: current approach and future directions.</TI>
<SO>Critical Reviews in Oncology Hematology</SO>
<YR>2006</YR>
<VL>58</VL>
<PG>257-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Czuczman-1999" NAME="Czuczman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al.</AU>
<TI>Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>268-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Czuczman-2004" NAME="Czuczman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ</AU>
<TI>Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>23</NO>
<PG>4711-4716</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demidem-1997" NAME="Demidem 1997" TYPE="JOURNAL_ARTICLE">
<AU>Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B</AU>
<TI>Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs</TI>
<SO>Cancer Biotherapy &amp; Radiopharmaceuticals</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>3</NO>
<PG>177-186</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dreyling-2006" NAME="Dreyling 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dreyling M, Forstpointner R, Gramatzki M, Bock H, Hanel M, Seymour J et al.</AU>
<TI>Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24 (Suppl)</VL>
<PG>7502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feugier-2005" NAME="Feugier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al.</AU>
<TI>Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4117-4126</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-1993" NAME="Fisher 1993" TYPE="JOURNAL_ARTICLE">
<AU>Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al.</AU>
<TI>Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>14</NO>
<PG>1002-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallagher-1986" NAME="Gallagher 1986" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al.</AU>
<TI>Follicular lymphoma: prognostic factors for response and survival</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>10</NO>
<PG>1470-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Habermann-2005" NAME="Habermann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Habermann TM</AU>
<TI>Diffuse large B-cell lymphoma</TI>
<SO>Clinal Advances in Hematology Oncology: H&amp;O</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>11</NO>
<PG>suppl-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horning-1993" NAME="Horning 1993" TYPE="JOURNAL_ARTICLE">
<AU>Horning SJ</AU>
<TI>Natural history of and therapy for the indolent non-Hodgkin's lymphomas</TI>
<SO>Seminars Oncology</SO>
<YR>1993</YR>
<VL>20</VL>
<NO>5 Suppl 5</NO>
<PG>75-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ihaka-1996" NAME="Ihaka 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ihaka R, Gentleman R</AU>
<TI>a language for data analysis and graphics</TI>
<SO>J Computat Graph Stat</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>299-314</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imrie-2005" NAME="Imrie 2005" TYPE="JOURNAL_ARTICLE">
<AU>Imrie K, Stevens A, Meyer R, the members of the Hematology Disease Site Group</AU>
<TI>Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Systematic Review. Evidence-based Series 6-8</TI>
<SO>Cancer Care Ontario, Program in Evidence-Based Care (PEBC)</SO>
<YR>2005</YR>
<VL>2</VL>
<PG>6-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jazirehi-2005" NAME="Jazirehi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Jazirehi AR, Bonavida B</AU>
<TI>Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention</TI>
<SO>Oncogene</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>13</NO>
<PG>2121-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jazirehi-2005a" NAME="Jazirehi 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B</AU>
<TI>Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis</TI>
<SO>Cancer Reserach</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>1</NO>
<PG>264-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kober-2002" NAME="Kober 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kober T, Klein TO, Bohlius J, Engert A.</AU>
<TI>Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. (Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>No.: CD003805. DOI: 10.1002/14651858.CD003805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landis-1998" NAME="Landis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Landis SH, Murray T, Bolden S and Wingo PA</AU>
<TI>Cancer statistics, 1998 Cancer statistics, 1998 Cancer statistics, 1998</TI>
<SO>CA: A Cancer Journal for Clinicans</SO>
<YR>1998</YR>
<VL>48</VL>
<PG>6-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2006" NAME="Liu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al.</AU>
<TI>Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>10</NO>
<PG>1582-1589</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLaughlin-1986" NAME="McLaughlin 1986" TYPE="JOURNAL_ARTICLE">
<AU>McLaughlin P, Fuller LM, Velasquez WS, Sullivan Halley JA, Butler JJ, Cabanillas F</AU>
<TI>Stage I-II follicular lymphoma treatment results for 76 patients</TI>
<SO>Cancer</SO>
<YR>1986</YR>
<VL>58</VL>
<PG>1596-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLaughlin-1998" NAME="McLaughlin 1998" TYPE="JOURNAL_ARTICLE">
<AU>McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al.</AU>
<TI>Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>8</NO>
<PG>2825-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montoto-2003" NAME="Montoto 2003" TYPE="JOURNAL_ARTICLE">
<AU>Montoto S, Lopez-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A, Villamor N, Moreno C, Campo E, Montserrat E</AU>
<TI>Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma</TI>
<SO>Leul Lymphoma</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>1</NO>
<PG>71-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri VaS</AU>
<TI>Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenberg-1971" NAME="Rosenberg 1971" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg SA, Boiron M, DeVita V, Johnson RE, Lee BJ, Ultmann JE.</AU>
<TI>Report of the committee on Hodgkin&#8217;s disease staging procedures.</TI>
<SO>Cancer Research</SO>
<YR>1971</YR>
<VL>31</VL>
<PG>1862-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solal_x002d_Celigny-2004" NAME="Solal-Celigny 2004" TYPE="JOURNAL_ARTICLE">
<AU>Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al.</AU>
<TI>Follicular lymphoma international prognostic index</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>5</NO>
<PG>1258-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swenson-2005" NAME="Swenson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK</AU>
<TI>Improved survival of follicular lymphoma patients in the United States</TI>
<SO>J Clin Oncol</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>22</NO>
<PG>5019-5026</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-2001" NAME="Williams 2001" TYPE="JOURNAL_ARTICLE">
<AU>Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B.</AU>
<TI>High-dose therapy and autologous stem cell support for chemosensitive transformed low-grade follicular non-Hodgkin&#8217;s lymphoma: a case-matched study for the European Bone Marrow Transplant Registry.</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zinzani-1998" NAME="Zinzani 1998" TYPE="JOURNAL_ARTICLE">
<AU>Zinzani PL, Magagnoli M, Gherlinzoni F, Bendandi M, Albertini P, Merla E, et al.</AU>
<TI>To what extent can indolent lymphoma be considered? Results of a long term follow-up study from a single center.</TI>
<SO>Haematologica</SO>
<YR>1998</YR>
<VL>83</VL>
<PG>502-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Schulz-2007" NAME="Schulz 2007" TYPE="JOURNAL_ARTICLE">
<AU>Schulz H, Bohlius J, Trelle S, Skoetz N, Reiser M, Kober T, et al.</AU>
<TI>Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis</TI>
<SO>Journalof National Cnacer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<PG>706-14</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-19 16:50:25 +0200" MODIFIED_BY="Nicole Skoetz">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-19 16:49:14 +0200" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Forstpointner-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Blind: No<BR/>Withdrawls: Yes<BR/>ITT: yes<BR/>Placebo:No<BR/>Funding: Deutsche Krebshilfe</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Relapsed or refractory indolent and mantle cell lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 x R-FCM vs 4 x FCM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Progression free survival<BR/>Complete Response <BR/>Partial Response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Second randomisation for maintenance 4xRituximab month 3 and months 9 vs observation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:48:38 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Herold-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Blind: No<BR/>Withdrawls: No<BR/>ITT: yes<BR/>Placebo:No<BR/>Funding: pharmaceutical</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Untreated indolent and mantle cell lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-19 16:48:38 +0200" MODIFIED_BY="Nicole Skoetz">
<P>6 x R-MCP vs 6 x MCP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Progression free survival<BR/>Event free survival<BR/>Complete Response <BR/>Partial Response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Interferon maintenance therapy for follicular lymphoma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:48:46 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Hiddemann-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Blind: No<BR/>Withdrawls: No<BR/>ITT: Deutsche Krebshilfe<BR/>Placebo:No<BR/>Funding: pharmaceutical</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Untreated indolent and mantle cell lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6-8 R-CHOP vs 6-8 CHOP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Time to treatment failure<BR/>Complete Response <BR/>Partial Response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-19 16:48:46 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Second randomisation for patients &lt; 60 years for PBSCT vs Interferon maintenance<BR/>and for patients &gt; 60 years intensive interferon vs standard maintenance<BR/>patients in CR after 4 cycles received only 6 cycles of therapy whereas all others received 8 cycles. Progressive disease were taken off study after 4 at any time</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:48:54 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Lenz-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Blind: No<BR/>Withdrawls: Yes<BR/>ITT: yes<BR/>Placebo:No<BR/>Funding: Deutsche Krebshilfe pharmaceutical</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Untreated mantle cell lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-19 16:48:50 +0200" MODIFIED_BY="Nicole Skoetz">
<P>6 x R-CHOP vs 6 x CHOP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Progression free survival<BR/>Time to treatment failure<BR/>Complete Response <BR/>Partial Response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-19 16:48:54 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Second randomisation for patients &lt; 65 years for PBSCT vs Interferon maintenance plus 2 cycles of conventional chemotherapy<BR/>and all patients &gt; 65 years received interferon standard maintenance<BR/>therapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:48:58 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Marcus-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Blind: No<BR/>Withdrawls: Yes<BR/>ITT: yes<BR/>Placebo:No<BR/>Funding: pharmaceutical</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Untreated indolent lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-19 16:48:58 +0200" MODIFIED_BY="Nicole Skoetz">
<P>8 x R-CVP vs 8 x CVP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Progression free survival<BR/>Duration of response<BR/>Complete Response <BR/>Partial Response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Restaging were done after 4 cycles and patients with stable disease were taken off study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rivas_x002d_Vera-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Blind: No<BR/>Withdrawls: Yes<BR/>ITT: yes<BR/>Placebo:No<BR/>Funding: not applicable</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Untreated indolent lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>R-CNOP vs CNOP vs R</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Time to progressionOverall survival<BR/>Time to progression<BR/>Complete Response<BR/>Partial Response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>subgroups of indolent lymphoma are not specified. Three arm study. Patients with R only are not included in the meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:49:14 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-van-Oers-2006">
<CHAR_METHODS>
<P>Randomised<BR/>Blind: No<BR/>Withdrawls: Yes<BR/>ITT: yes<BR/>Placebo:No<BR/>Funding:</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Relapsed or refractory indolent lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6 x R-CHOP vs 6 x CHOP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall survival<BR/>Time to progression<BR/>Complete Response<BR/>Partial Response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-19 16:49:14 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Second randomisation for maintenance therapy with rituximab every 2 month until 2 years vs observation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-08-19 16:50:25 +0200" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Byrd-JC">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of concurrent vs sequential treatment with rituximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rituximab Konsolidationtherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:49:23 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Czuczman">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:49:23 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Non randomised study<BR/>6 x Rituximab + 6 x R-CHOP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:49:25 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Czuczman-M">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:49:25 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Non randomised study<BR/>7 x Rituximab + 6 x Fludarabin<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doelken-G">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study focused on rapid clearence of circulating lymphoma cells but had no outcome analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ghielmeni-M">
<CHAR_REASON_FOR_EXCLUSION>
<P>Monotherapy R and maintenance rituximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gregory-S">
<CHAR_REASON_FOR_EXCLUSION>
<P>Konsoldiationtherapy with Rituximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hainsworth-J">
<CHAR_REASON_FOR_EXCLUSION>
<P>No identical chemotherapy and furthermore rituximab monotherapy as induction followed by R-CVP or R-CHOP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hochster-H">
<CHAR_REASON_FOR_EXCLUSION>
<P>rituximab maintenance therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:49:52 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Huang-J">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:49:52 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Non randomised study<BR/>6 x R-CHOP followed by 4 x rituximab every 6 months for 2 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:49:46 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Jiang-Y">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:49:46 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Sequential vs concurrent therapy with rituximab<BR/>6 x R-FND vs FND followed by 6 x R</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:49:41 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Katakkar-S">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:49:41 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Non randomised study<BR/>6 x Rituximab weekly + CVP<BR/>and maintenance therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:49:58 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Meckenstock-G">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:49:58 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Standard chemotherapy with rituximab vs high dose therapy with rituximab and no identical chemotherapy in both arms<BR/>6 x FMR vs 3 x R-CHOP 2 x HAM/R and PBSCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pettengell">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rituximab maintenance therapy and ongoing trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rambaldi-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment outcome was minimal residual disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:50:05 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Rule-S">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:50:05 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Non randomised study and ongoing trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:50:17 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Salles-G">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:50:17 +0200" MODIFIED_BY="Nicole Skoetz">
<P>No identical chemotherapy schedule.<BR/>6 x R-CHVP vs<BR/>12 x CVHP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Solal_x002d_Celigny-P">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rituximab monotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tobinai">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rituximab concurrent vs sequential <BR/>6 x R-CHOP<BR/>6 x CHOP 6 x R</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-19 16:50:25 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Vitolo">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-19 16:50:25 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Rituximab consolidationtherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Witzig">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rituximab mono</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zinzani-PL">
<CHAR_REASON_FOR_EXCLUSION>
<P>Konsolidationtherapy with rituximab after 6 x Fludara + Mitoxantrone vs 6 x R-CHOP.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-GELA-Study">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Sonneveld">
<CHAR_STUDY_NAME>
<P>Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Adult Diffuse Large Cell Lymphoma<BR/>Adult Non-Hodgkin's Lymphoma<BR/>Grade 3 Follicular Lymphoma<BR/>Mantle Cell Lymphoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Compare the efficacy of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), and filgrastim (G-CSF) with or without rituximab on event-free survival of elderly patients with intermediate or high-risk non-Hodgkin's lymphoma.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Compare the complete remission rate, overall survival, and disease-free survival of patients treated with these regimens. <BR/>Compare the toxicity of these regimens in these patients</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Sponsored by: Commissie Voor Klinisch Toegepast Onderzoek <BR/>Information provided by: National Cancer Institute (NCI) <BR/>ClinicalTrials.gov Identifier: NCT00028717 <BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Forstpointner-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Herold-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hiddemann-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lenz-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Marcus-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rivas_x002d_Vera-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-van-Oers-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-08-19 16:52:13 +0200" MODIFIED_BY="Nicole Skoetz">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-08-19 16:51:46 +0200" MODIFIED_BY="Nicole Skoetz" NO="1">
<TITLE>Trials included in the Meta-Analysis</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Total Group (N)</P>
</TH>
<TH>
<P>FL (N)</P>
</TH>
<TH>
<P>MCL (N)</P>
</TH>
<TH>
<P>Unspecified lymphoma</P>
</TH>
</TR>
<TR>
<TD>
<P>Forstpointner 2004</P>
</TD>
<TD>
<P>128</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>Herold 2004</P>
</TD>
<TD>
<P>358</P>
</TD>
<TD>
<P>201</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>67</P>
</TD>
</TR>
<TR>
<TD>
<P>Hiddemann 2005</P>
</TD>
<TD>
<P>428</P>
</TD>
<TD>
<P>428</P>
</TD>
<TD>
<P>not included</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Lenz 2005</P>
</TD>
<TD>
<P>122</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>122</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Marcus 2005</P>
</TD>
<TD>
<P>321</P>
</TD>
<TD>
<P>321</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Rivas-Vera 2005</P>
</TD>
<TD>
<P>121</P>
</TD>
<TD>
<P>not applicable</P>
</TD>
<TD>
<P>not applicable</P>
</TD>
<TD>
<P>121</P>
</TD>
</TR>
<TR>
<TD>
<P>van Oers 2006</P>
</TD>
<TD>
<P>465</P>
</TD>
<TD>
<P>465</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Total amount</P>
</TD>
<TD>
<P>1943</P>
</TD>
<TD>
<P>1480</P>
</TD>
<TD>
<P>260</P>
</TD>
<TD>
<P>203</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-08-19 16:52:13 +0200" MODIFIED_BY="Nicole Skoetz" NO="2">
<TITLE>Characteristics of the included studies</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Therapy</P>
</TH>
<TH>
<P>Previous therapy</P>
</TH>
<TH>
<P>Ann Arbor stage</P>
</TH>
<TH>
<P>High FLIPI risk</P>
</TH>
<TH>
<P>Observation time</P>
</TH>
</TR>
<TR>
<TD>
<P>Forstpointner 2004</P>
</TD>
<TD>
<P>4 x R-FCM vs 4 x FCM</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>III/IV</P>
</TD>
<TD>
<P>not applicable</P>
</TD>
<TD>
<P>18 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Herold 2004</P>
</TD>
<TD>
<P>8 x R-MCP vs 8 x MCP</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>III/IV</P>
</TD>
<TD>
<P>55%</P>
</TD>
<TD>
<P>36 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Hiddemann 2005</P>
</TD>
<TD>
<P>6-8 x R-CHOP vs 6 to 8 x CHOP</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>III/IV</P>
</TD>
<TD>
<P>45%</P>
</TD>
<TD>
<P>36 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Lenz 2005</P>
</TD>
<TD>
<P>6 x R-CHOP vs 6 x CHOP</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>III/IV</P>
</TD>
<TD>
<P>35 % (IPI high and high-intermediate risk)</P>
</TD>
<TD>
<P>18 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Marcus 2005</P>
</TD>
<TD>
<P>8 x R-CVP vs 8 CVP</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>III/IV</P>
</TD>
<TD>
<P>45%</P>
</TD>
<TD>
<P>18 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Rivas-Vera 2005</P>
</TD>
<TD>
<P>6 x R-CNOP vs 6 x CNOP vs 6 x R</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>III/IV</P>
</TD>
<TD>
<P>not applicable</P>
</TD>
<TD>
<P>24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>van Oers 2006</P>
</TD>
<TD>
<P>8 x R-CHOP vs 8 x CHOP</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>III/IV</P>
</TD>
<TD>
<P>37%</P>
</TD>
<TD>
<P>39 months</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Quality assessment of the included studies</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>ITT- Analysis</P>
</TH>
<TH>
<P>Allocation concealed</P>
</TH>
<TH>
<P>Drop outs</P>
</TH>
<TH>
<P>Source of data</P>
</TH>
</TR>
<TR>
<TD>
<P>Forstpointner 2004</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>13%</P>
</TD>
<TD>
<P>Full text</P>
</TD>
</TR>
<TR>
<TD>
<P>Herold 2004</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>Abstract</P>
</TD>
</TR>
<TR>
<TD>
<P>Hiddemann 2005</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>Full text</P>
</TD>
</TR>
<TR>
<TD>
<P>Lenz 2005</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>5%</P>
</TD>
<TD>
<P>Full text</P>
</TD>
</TR>
<TR>
<TD>
<P>Marcus 2005</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>1%</P>
</TD>
<TD>
<P>Full text</P>
</TD>
</TR>
<TR>
<TD>
<P>Rivas-Vera 2005</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>13%</P>
</TD>
<TD>
<P>Abstract</P>
</TD>
</TR>
<TR>
<TD>
<P>van Oers 2006</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>Full text</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-19 16:16:12 +0200" MODIFIED_BY="Nicole Skoetz">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-19 16:12:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="1">
<NAME>Overall survival</NAME>
<IPD_OUTCOME CHI2="4.416141734664235" CI_END="0.7847957258348285" CI_START="0.5356480879282356" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6483628073522398" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10524337088218981" LOG_CI_START="-0.27112044102447325" LOG_EFFECT_SIZE="-0.18818190595333154" NO="1" P_CHI2="0.6205504983026155" P_Q="1.0" P_Z="8.706761400329061E-6" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="949" WEIGHT="99.99999999999999" Z="4.447025232532313">
<NAME>Overall survival Total group</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19863" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="10.908573056109368"/>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19864" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="20.886736922054492"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19865" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="20.848761036741667"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19866" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="4.984334947308458"/>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19867" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="11.63011487705307"/>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19868" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="2.971613025728662"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19869" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="27.769866135004268"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="8.075275822212653" CI_END="0.7706351252019794" CI_START="0.5120163037145945" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="0.6281542392745203" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="188" I2="13.315654423281654" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.11315119992496525" LOG_CI_START="-0.29071620992153124" LOG_EFFECT_SIZE="-0.20193370492324822" NO="2" P_CHI2="0.3260031411620343" P_Q="0.8428923745992337" P_Z="8.276971265836882E-6" Q="0.03928136676324101" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="889" TOTAL_2="851" WEIGHT="100.0" Z="4.457891663700628">
<NAME>Overall survival FL vs MCL</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="2.8281517519163852" CI_END="0.7941064628154396" CI_START="0.5064036696994522" DF="4.0" EFFECT_SIZE="0.6341438534763151" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="142" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.10012126946990792" LOG_CI_START="-0.2955031558255201" LOG_EFFECT_SIZE="-0.19781221264771404" NO="1" P_CHI2="0.5869830940413155" P_Z="7.226962029965349E-5" STUDIES="5" TAU2="0.0" TOTAL_1="759" TOTAL_2="721" WEIGHT="82.59355961705832" Z="3.9686873714182624">
<NAME>Follicular lymphoma</NAME>
<IPD_DATA CI_END="1.180074997850788" CI_START="0.12182431544992191" EFFECT_SIZE="0.3791593712315975" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.07190960910080775" LOG_CI_START="-0.9142660203091285" LOG_EFFECT_SIZE="-0.4211782056041603" ORDER="19870" O_E="-2.89" SE="0.5792844463634923" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="35" TOTAL_2="30" VAR="2.98" WEIGHT="3.2419495213228897"/>
<IPD_DATA CI_END="0.8504782015645866" CI_START="0.23809395462333338" EFFECT_SIZE="0.449993020314152" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" LOG_CI_END="-0.07033681322311791" LOG_CI_START="-0.6232516315042272" LOG_EFFECT_SIZE="-0.34679422236367263" ORDER="19871" O_E="-7.57" SE="0.32478490123081544" STUDY_ID="STD-Herold-2004" TOTAL_1="105" TOTAL_2="96" VAR="9.48" WEIGHT="10.313315926892951"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19872" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="23.89033942558747"/>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19873" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="13.32680591818973"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19874" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="31.821148825065276"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="5.207842703533026" CI_END="0.980189847769973" CI_START="0.3678827535231739" DF="2.0" EFFECT_SIZE="0.6004955788122659" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="46" I2="61.596382343821745" ID="CMP-001.02.02" LOG_CI_END="-0.008689799966944455" LOG_CI_START="-0.4342905715743724" LOG_EFFECT_SIZE="-0.22149018577065843" NO="2" P_CHI2="0.07398301137703556" P_Z="0.041350325733545634" STUDIES="3" TAU2="0.0" TOTAL_1="130" TOTAL_2="130" WEIGHT="17.40644038294169" Z="2.04">
<NAME>Mantlecell lymphoma</NAME>
<IPD_DATA CI_END="0.5934824716371079" CI_START="0.061734085128213795" EFFECT_SIZE="0.19141080801811572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.2265921033036545" LOG_CI_START="-1.2094749835230982" LOG_EFFECT_SIZE="-0.7180335434133763" ORDER="19875" O_E="-4.96" SE="0.5773502691896257" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="24" TOTAL_2="24" VAR="3.0" WEIGHT="3.2637075718015667"/>
<IPD_DATA CI_END="1.3729244127059288" CI_START="0.335834560076314" EFFECT_SIZE="0.6790253796134039" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.13764662751471504" LOG_CI_START="-0.47387461350432925" LOG_EFFECT_SIZE="-0.16811399299480714" ORDER="19876" O_E="-3.0" SE="0.3592106040535498" STUDY_ID="STD-Herold-2004" TOTAL_1="44" TOTAL_2="46" VAR="7.75" WEIGHT="8.43124456048738"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19877" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="5.711488250652741"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.416141734664235" CI_END="0.7847957258348285" CI_START="0.5356480879282356" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6483628073522398" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="208" I2="0.0" I2_Q="14.83934340691052" ID="CMP-001.03" LOG_CI_END="-0.10524337088218981" LOG_CI_START="-0.27112044102447325" LOG_EFFECT_SIZE="-0.18818190595333154" NO="3" P_CHI2="0.6205504983026155" P_Q="0.27852951351230326" P_Z="8.706761400329061E-6" Q="1.174251162456569" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="949" WEIGHT="99.99999999999999" Z="4.447025232532313">
<NAME>Sensitivity: attrition bias</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.5177172363390201" CI_END="0.8309980025851698" CI_START="0.5506233247280512" DF="4.0" EFFECT_SIZE="0.6764369024719274" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="172" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.08040002009950077" LOG_CI_START="-0.25914539558320915" LOG_EFFECT_SIZE="-0.16977270784135495" NO="1" P_CHI2="0.8234986320627722" P_Z="1.9674844275897817E-4" STUDIES="5" TAU2="0.0" TOTAL_1="862" TOTAL_2="832" WEIGHT="86.11981391816195" Z="3.723155265152296">
<NAME>Less than 10% excluded from analysis</NAME>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19878" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="20.886736922054492"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19879" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="20.848761036741667"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19880" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="4.984334947308458"/>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19881" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="11.63011487705307"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19882" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="27.769866135004268"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.7241733358686455" CI_END="0.8321759489386915" CI_START="0.29852503638866057" DF="1.0" EFFECT_SIZE="0.498422868093641" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" I2="42.00119099416441" ID="CMP-001.03.02" LOG_CI_END="-0.07978484008614996" LOG_CI_START="-0.5250192400472431" LOG_EFFECT_SIZE="-0.3024020400666965" NO="2" P_CHI2="0.18915682922261357" P_Z="0.007758450678472647" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="117" WEIGHT="13.88018608183803" Z="2.662404825116642">
<NAME>More than 10% excluded from analysis</NAME>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19883" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="10.908573056109368"/>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19884" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="2.971613025728662"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.320413094034234" CI_END="0.7857708462119517" CI_START="0.5234085507778592" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="0.641310517502473" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="180" I2="0.0" I2_Q="12.964283610636311" ID="CMP-001.04" LOG_CI_END="-0.1047040884844498" LOG_CI_START="-0.28115918669173123" LOG_EFFECT_SIZE="-0.19293163758809048" NO="4" P_CHI2="0.504264971135729" P_Q="0.28376834929328965" P_Z="1.819580849320165E-5" Q="1.1489536037439985" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="832" TOTAL_2="790" WEIGHT="100.0" Z="4.285952233658815">
<NAME>Overall survival_Doxorubicin vs Mitoxantrone</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.1304043124607661" CI_END="0.9103534435775625" CI_START="0.5403130881040565" DF="2.0" EFFECT_SIZE="0.7013386345878536" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="93" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.040789960652835695" LOG_CI_START="-0.26735451233767565" LOG_EFFECT_SIZE="-0.15407223649525564" NO="1" P_CHI2="0.5682454173649094" P_Z="0.007682928332318216" STUDIES="3" TAU2="0.0" TOTAL_1="519" TOTAL_2="496" WEIGHT="60.657498925655354" Z="2.665695337621035">
<NAME>Doxorubicin based regimen</NAME>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19885" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="23.592608508809626"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19886" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="5.640309411259132"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19887" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="31.424581005586592"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.0410551778294694" CI_END="0.772354259358361" CI_START="0.40410558178522255" DF="2.0" EFFECT_SIZE="0.5586704460791756" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="87" I2="2.0114682971544635" ID="CMP-001.04.02" LOG_CI_END="-0.11218345407502804" LOG_CI_START="-0.39350515074077363" LOG_EFFECT_SIZE="-0.2528443024079009" NO="2" P_CHI2="0.3604048784843312" P_Z="4.264904461477861E-4" STUDIES="3" TAU2="0.0" TOTAL_1="313" TOTAL_2="294" WEIGHT="39.34250107434465" Z="3.523124823212266">
<NAME>Mitoxantrone based regimen</NAME>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19888" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="12.344220025784272"/>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19889" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="23.635582294800173"/>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19890" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="3.362698753760206"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.416141734664235" CI_END="0.7847957258348285" CI_START="0.5356480879282356" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6483628073522398" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.10524337088218981" LOG_CI_START="-0.27112044102447325" LOG_EFFECT_SIZE="-0.18818190595333154" NO="5" P_CHI2="0.6205504983026155" P_Q="0.8246953220198923" P_Z="8.706761400329061E-6" Q="0.04906669725816837" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="949" WEIGHT="100.0" Z="4.447025232532313">
<NAME>Overall survival untreated vs treated patients</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.6100360095716333" CI_END="0.8417354365605145" CI_START="0.5168319719869735" DF="4.0" EFFECT_SIZE="0.6595724263254845" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="113" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.07482438890021925" LOG_CI_START="-0.2866506280856736" LOG_EFFECT_SIZE="-0.18073750849294645" NO="1" P_CHI2="0.8069872425857338" P_Z="8.239574351324945E-4" STUDIES="5" TAU2="0.0" TOTAL_1="694" TOTAL_2="656" WEIGHT="61.32156080888635" Z="3.344618765492411">
<NAME>Untreated patients</NAME>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19891" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="20.886736922054492"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19892" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="20.848761036741667"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19893" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="4.984334947308458"/>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19894" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="11.63011487705307"/>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19895" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="2.971613025728662"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.757039027834433" CI_END="0.8577771325320401" CI_START="0.46414826842332524" DF="1.0" EFFECT_SIZE="0.6309800082077653" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="95" I2="63.72920405172979" ID="CMP-001.05.02" LOG_CI_END="-0.06662553579282687" LOG_CI_START="-0.33334326541016784" LOG_EFFECT_SIZE="-0.19998440060149736" NO="2" P_CHI2="0.09682738144469882" P_Z="0.0032910964911844576" STUDIES="2" TAU2="0.0" TOTAL_1="300" TOTAL_2="293" WEIGHT="38.67843919111364" Z="2.939153862858027">
<NAME>Treated patients</NAME>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19896" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="10.908573056109368"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19897" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="27.769866135004268"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.416141734664222" CI_END="0.7847957258348284" CI_START="0.5356480879282355" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6483628073522397" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.10524337088218987" LOG_CI_START="-0.27112044102447336" LOG_EFFECT_SIZE="-0.18818190595333162" NO="6" P_CHI2="0.6205504983026171" P_Q="0.7570169465519228" P_Z="8.706761400329061E-6" Q="0.09572864062999287" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="949" WEIGHT="100.0" Z="4.447025232532313">
<NAME>Overall survival_Anthracylin vs no-Anthracylin treatment</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.32041309403423" CI_END="0.7857708462119516" CI_START="0.5234085507778592" DF="5.0" EFFECT_SIZE="0.6413105175024729" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="180" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.10470408848444986" LOG_CI_START="-0.28115918669173123" LOG_EFFECT_SIZE="-0.19293163758809057" NO="1" P_CHI2="0.5042649711357297" P_Z="1.819580849320158E-5" STUDIES="6" TAU2="0.0" TOTAL_1="832" TOTAL_2="790" WEIGHT="88.36988512294693" Z="4.285952233658816">
<NAME>Anthracyclin based regimen</NAME>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19898" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="10.90857305610937"/>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19899" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="20.886736922054496"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19900" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="20.84876103674167"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19901" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="4.984334947308459"/>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19902" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="2.971613025728662"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19903" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="27.76986613500427"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.233413622559709" CI_START="0.40244622581791484" DF="0.0" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" NO="2" P_CHI2="1.0" P_Z="0.22030623543317396" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="159" WEIGHT="11.630114877053071" Z="1.2257142857142858">
<NAME>No anthracylin based regimen</NAME>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19904" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="11.630114877053071"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.416141734664228" CI_END="0.7847957258348285" CI_START="0.5356480879282355" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6483628073522398" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.10524337088218981" LOG_CI_START="-0.27112044102447336" LOG_EFFECT_SIZE="-0.18818190595333154" NO="7" P_CHI2="0.6205504983026164" P_Q="0.9324005013643991" P_Z="8.706761400329061E-6" Q="0.007195284234580157" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="949" WEIGHT="100.0" Z="4.447025232532313">
<NAME>Overall survival_Full Text vs Abstract Publication</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.8087235056241355" CI_END="0.8107292968917851" CI_START="0.523333925065877" DF="4.0" EFFECT_SIZE="0.6513694382670072" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="151" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.0911241328313165" LOG_CI_START="-0.2812211112543143" LOG_EFFECT_SIZE="-0.18617262204281546" NO="1" P_CHI2="0.43251087161486845" P_Z="1.235338687277287E-4" STUDIES="5" TAU2="0.0" TOTAL_1="747" TOTAL_2="717" WEIGHT="76.14165005221685" Z="3.839005092436141">
<NAME>Full-text</NAME>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19905" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="10.90857305610937"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19906" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="20.84876103674167"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19907" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="4.984334947308459"/>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19908" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="11.630114877053071"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19909" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="27.76986613500427"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.6002229448055121" CI_END="0.9445067338590981" CI_START="0.4321218764517853" DF="1.0" EFFECT_SIZE="0.6388599393893316" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.024794941429365006" LOG_CI_START="-0.3643937466908591" LOG_EFFECT_SIZE="-0.19459434406011203" NO="2" P_CHI2="0.438493140193439" P_Z="0.024693278744841125" STUDIES="2" TAU2="0.0" TOTAL_1="247" TOTAL_2="232" WEIGHT="23.858349947783157" Z="2.2461675367752583">
<NAME>Abstract Form</NAME>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19910" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="20.886736922054496"/>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19911" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="2.971613025728662"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.416141734664222" CI_END="0.7847957258348284" CI_START="0.5356480879282355" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6483628073522397" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.10524337088218987" LOG_CI_START="-0.27112044102447336" LOG_EFFECT_SIZE="-0.18818190595333162" NO="8" P_CHI2="0.6205504983026171" P_Q="0.47808495298514586" P_Z="8.706761400329061E-6" Q="0.5032286683394638" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="949" WEIGHT="100.00000000000003" Z="4.447025232532313">
<NAME>Overall survival_Alloc. concealment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.9129130663247587" CI_END="0.7776133928894073" CI_START="0.5276740340269356" DF="5.0" EFFECT_SIZE="0.6405672454468195" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="202" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-0.10923626813337979" LOG_CI_START="-0.2776342762156618" LOG_EFFECT_SIZE="-0.1934352721745208" NO="1" P_CHI2="0.5620214124713303" P_Z="6.70831448807575E-6" STUDIES="6" TAU2="0.0" TOTAL_1="928" TOTAL_2="894" WEIGHT="97.02838697427137" Z="4.502739327136417">
<NAME>Adaequate</NAME>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19912" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="10.908573056109374"/>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19913" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="20.8867369220545"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19914" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="20.848761036741674"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19915" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="4.98433494730846"/>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19916" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="11.630114877053074"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19917" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="27.76986613500428"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.913917762453919" CI_START="0.3178499693159195" DF="0.0" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" NO="2" P_CHI2="1.0" P_Z="0.9459225461284596" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="55" WEIGHT="2.971613025728663" Z="0.06782801027330657">
<NAME>Not adaequate</NAME>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19918" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="2.971613025728663"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.416141734664228" CI_END="0.7847957258348285" CI_START="0.5356480879282355" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6483628073522398" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.10524337088218981" LOG_CI_START="-0.27112044102447336" LOG_EFFECT_SIZE="-0.18818190595333154" MODIFIED="2008-08-19 16:12:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="9" P_CHI2="0.6205504983026164" P_Q="0.8951887791508659" P_Z="8.706761400329061E-6" Q="0.017355817948431884" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="994" TOTAL_2="949" WEIGHT="100.0" Z="4.447025232532313">
<NAME>Overall Survival _with or without second randomisation</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.6791003381014087" CI_END="0.9089876676586169" CI_START="0.47875228396850594" DF="2.0" EFFECT_SIZE="0.6596816823216847" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="85" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-0.04144200886179854" LOG_CI_START="-0.31988914114331474" LOG_EFFECT_SIZE="-0.18066557500255664" NO="1" P_CHI2="0.7120906478730527" P_Z="0.010978669314148724" STUDIES="3" TAU2="0.0" TOTAL_1="409" TOTAL_2="391" WEIGHT="35.48846482483623" Z="2.5433770306761865">
<NAME>No second randomisation</NAME>
<IPD_DATA CI_END="0.9153050229631677" CI_START="0.3968371190717692" EFFECT_SIZE="0.6026831741343233" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" LOG_CI_END="-0.03843415433278366" LOG_CI_START="-0.40138771188560046" LOG_EFFECT_SIZE="-0.21991093310919205" ORDER="19919" O_E="-11.14" SE="0.21320071635561044" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="22.0" WEIGHT="20.886736922054496"/>
<IPD_DATA CI_END="1.233413622559709" CI_START="0.40244622581791484" EFFECT_SIZE="0.7045442904967416" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.0911087407254731" LOG_CI_START="-0.3952921411115874" LOG_EFFECT_SIZE="-0.15209170019305712" ORDER="19920" O_E="-4.29" SE="0.2857142857142857" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="12.25" WEIGHT="11.630114877053071"/>
<IPD_DATA CI_END="2.913917762453919" CI_START="0.3178499693159195" EFFECT_SIZE="0.9623869655108028" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.46447729080512845" LOG_CI_START="-0.49777782615873256" LOG_EFFECT_SIZE="-0.016650267676802" ORDER="19921" O_E="-0.12" SE="0.5652334189442215" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="3.13" WEIGHT="2.971613025728662"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.719685578614387" CI_END="0.8146003686026242" CI_START="0.5063163624379048" DF="3.0" EFFECT_SIZE="0.6422191958135922" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="123" I2="19.348021853031888" ID="CMP-001.09.02" LOG_CI_END="-0.08905539773387884" LOG_CI_START="-0.29557803745284217" LOG_EFFECT_SIZE="-0.1923167175933605" NO="2" P_CHI2="0.2933675167123696" P_Z="2.6194363692648263E-4" STUDIES="4" TAU2="0.0" TOTAL_1="585" TOTAL_2="558" WEIGHT="64.51153517516377" Z="3.650290744112898">
<NAME>Second randomisation</NAME>
<IPD_DATA CI_END="0.7427983641713496" CI_START="0.23369060233276273" EFFECT_SIZE="0.41663532871684505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" LOG_CI_END="-0.12912906135678395" LOG_CI_START="-0.6313587520368998" LOG_EFFECT_SIZE="-0.3802439066968419" ORDER="19922" O_E="-10.06" SE="0.2950122063825638" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="11.49" WEIGHT="10.90857305610937"/>
<IPD_DATA CI_END="0.9152257902716429" CI_START="0.3965009970185096" EFFECT_SIZE="0.6024018080482161" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.03847175033552592" LOG_CI_START="-0.4017557162931802" LOG_EFFECT_SIZE="-0.22011373331435308" ORDER="19923" O_E="-11.13" SE="0.21339479988815996" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="21.96" WEIGHT="20.84876103674167"/>
<IPD_DATA CI_END="2.2643849418220277" CI_START="0.4092235687653856" EFFECT_SIZE="0.9626212583103545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.35495025816038106" LOG_CI_START="-0.38803936154348595" LOG_EFFECT_SIZE="-0.016544551691552438" ORDER="19924" O_E="-0.2" SE="0.4364357804719847" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="5.25" WEIGHT="4.984334947308459"/>
<IPD_DATA CI_END="1.0671180158555107" CI_START="0.5169374664789466" EFFECT_SIZE="0.7427201919635603" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="65" LOG_CI_END="0.02821245203981435" LOG_CI_START="-0.2865619899925179" LOG_EFFECT_SIZE="-0.12917476897635186" ORDER="19925" O_E="-8.7" SE="0.18490006540840973" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="29.25" WEIGHT="27.76986613500427"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-08-19 16:13:35 +0200" MODIFIED_BY="Nicole Skoetz" NO="2">
<NAME>Disease Control</NAME>
<IPD_OUTCOME CHI2="4.8756518045230495" CI_END="0.7109530872839481" CI_START="0.5480542962929645" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6242122186794445" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="529" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.1481590555373103" LOG_CI_START="-0.26117641339098163" LOG_EFFECT_SIZE="-0.20466773446414602" NO="1" P_CHI2="0.5598580046324853" P_Q="1.0" P_Z="1.2588378879281305E-12" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="978" TOTAL_2="935" WEIGHT="99.99999999999999" Z="7.098757146075016">
<NAME>FFS Total group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="0.974326674975792" CI_START="0.39725399369781106" EFFECT_SIZE="0.6221375754609606" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="-0.011295407235458329" LOG_CI_START="-0.40093172802315474" LOG_EFFECT_SIZE="-0.20611356762930652" ORDER="19926" O_E="-9.06" SE="0.22887430356158697" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="19.09" WEIGHT="8.413397972675186"/>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19927" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="17.078007933010138"/>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19928" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="9.78845306302336"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19929" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="6.941383869546056"/>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19930" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="21.154693697664168"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19931" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="6.765094755398854"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19932" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="29.858968708682237"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.109982589332559" CI_END="0.6735604767358866" CI_START="0.49982924468924333" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5802285966232833" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="414" I2="2.675986745491782" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.1716234043455486" LOG_CI_START="-0.3011783371739584" LOG_EFFECT_SIZE="-0.2364008707597535" NO="2" P_CHI2="0.39132618468546887" P_Q="0.7377552834554574" P_Z="8.50548055732084E-13" Q="0.11210943158784215" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="786" TOTAL_2="751" WEIGHT="100.0" Z="7.152752619874317">
<NAME>FFS_FL vs MCL</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.997873157744717" CI_END="0.6839992267191065" CI_START="0.5002123663985606" DF="3.0" EFFECT_SIZE="0.5849315103599309" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="378" I2="24.960100492723935" ID="CMP-002.02.01" LOG_CI_END="-0.1649443892620692" LOG_CI_START="-0.3008455757157365" LOG_EFFECT_SIZE="-0.2328949824889028" NO="1" P_CHI2="0.2616939602400513" P_Z="1.8472570288318215E-11" STUDIES="4" TAU2="0.0" TOTAL_1="724" TOTAL_2="691" WEIGHT="90.87855446806046" Z="6.717612844593651">
<NAME>Follicular lymphoma</NAME>
<IPD_DATA CI_END="0.6418893906100427" CI_START="0.26090979294026756" EFFECT_SIZE="0.4092373736532634" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="53" LOG_CI_END="-0.19253980243940594" LOG_CI_START="-0.583509619864506" LOG_EFFECT_SIZE="-0.388024711151956" ORDER="19933" O_E="-16.94" SE="0.22965760608731267" STUDY_ID="STD-Herold-2004" TOTAL_1="105" TOTAL_2="96" VAR="18.96" WEIGHT="10.980483002258643"/>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19934" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="12.86268604853188"/>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19935" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="27.79869114495859"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19936" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="39.23669427231134"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.8773077800259892" CI_START="0.32672827795513243" DF="0.0" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.056848019270897575" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" NO="2" P_CHI2="1.0" P_Z="0.013158630535225023" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="9.121445531939536" Z="2.479446942940531">
<NAME>Mantlecell lymphoma</NAME>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19937" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="9.121445531939536"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.875651804523068" CI_END="0.7109530872839482" CI_START="0.5480542962929645" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6242122186794447" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="529" I2="0.0" I2_Q="37.384529125819355" ID="CMP-002.03" LOG_CI_END="-0.14815905553731026" LOG_CI_START="-0.26117641339098163" LOG_EFFECT_SIZE="-0.20466773446414596" NO="3" P_CHI2="0.5598580046324828" P_Q="0.20632190656529115" P_Z="1.258837887928144E-12" Q="1.5970493969603732" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="978" TOTAL_2="935" WEIGHT="100.0" Z="7.098757146075014">
<NAME>FFS_Sensitivity: attrition bias</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.5368709371559324" CI_END="0.6938665882735122" CI_START="0.5230732707143341" DF="4.0" EFFECT_SIZE="0.6024475626704969" ESTIMABLE="YES" EVENTS_1="310" EVENTS_2="460" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.15872402456880635" LOG_CI_START="-0.2814374720541195" LOG_EFFECT_SIZE="-0.22008074831146285" NO="1" P_CHI2="0.820090916304402" P_Z="2.0623044682742267E-12" STUDIES="5" TAU2="0.0" TOTAL_1="862" TOTAL_2="832" WEIGHT="84.82150727192597" Z="7.0302049077827045">
<NAME>Less than 10% excluded from analysis</NAME>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19938" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="17.078007933010138"/>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19939" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="9.78845306302336"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19940" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="6.941383869546056"/>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19941" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="21.154693697664168"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19942" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="29.858968708682237"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.7417314704067623" CI_END="1.0629398640510819" CI_START="0.5450294695664445" DF="1.0" EFFECT_SIZE="0.7611396391496043" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="69" I2="42.585868316057876" ID="CMP-002.03.02" LOG_CI_END="0.026508694956463987" LOG_CI_START="-0.26358001492688027" LOG_EFFECT_SIZE="-0.11853565998520814" NO="2" P_CHI2="0.18691969568471467" P_Z="0.10920963940651596" STUDIES="2" TAU2="0.0" TOTAL_1="116" TOTAL_2="103" WEIGHT="15.17849272807404" Z="1.6017557149888428">
<NAME>More than 10% excluded from analysis</NAME>
<IPD_DATA CI_END="0.974326674975792" CI_START="0.39725399369781106" EFFECT_SIZE="0.6221375754609606" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="-0.011295407235458329" LOG_CI_START="-0.40093172802315474" LOG_EFFECT_SIZE="-0.20611356762930652" ORDER="19943" O_E="-9.06" SE="0.22887430356158697" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="19.09" WEIGHT="8.413397972675186"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19944" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="6.765094755398854"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.874802475793886" CI_END="0.7234475770860522" CI_START="0.5396695666730221" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="0.6248380913778205" ESTIMABLE="YES" EVENTS_1="303" EVENTS_2="414" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.14059293352505509" LOG_CI_START="-0.26787207220463266" LOG_EFFECT_SIZE="-0.20423250286484387" NO="4" P_CHI2="0.4313500379559625" P_Q="0.49010708704242834" P_Z="3.176119306511287E-10" Q="0.4762912493088942" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="816" TOTAL_2="776" WEIGHT="100.0" Z="6.289928644084945">
<NAME>Disease control_Doxorubicin vs Mitoxantrone</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.4657325690782306" CI_END="0.7242873995125585" CI_START="0.49468901955456784" DF="2.0" EFFECT_SIZE="0.5985791706538035" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="246" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-0.14008907019037367" LOG_CI_START="-0.3056677294170696" LOG_EFFECT_SIZE="-0.2228783998037216" NO="1" P_CHI2="0.48052976659045177" P_Z="1.3171148388624315E-7" STUDIES="3" TAU2="0.0" TOTAL_1="519" TOTAL_2="496" WEIGHT="59.088876467300175" Z="5.276448530110863">
<NAME>Doxorubicin based regimen</NAME>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19945" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="12.414756847400783"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19946" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="8.803801006148687"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19947" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="37.870318613750705"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.932778657406761" CI_END="0.8359771419668364" CI_START="0.5286910846794053" DF="2.0" EFFECT_SIZE="0.6648109971665901" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="168" I2="31.80528660255418" ID="CMP-002.04.02" LOG_CI_END="-0.07780559726599191" LOG_CI_START="-0.2767980130433172" LOG_EFFECT_SIZE="-0.17730180515465457" NO="2" P_CHI2="0.23075722472227844" P_Z="4.782579091639946E-4" STUDIES="3" TAU2="0.0" TOTAL_1="297" TOTAL_2="280" WEIGHT="40.91112353269983" Z="3.492647206071645">
<NAME>Mitoxantrone based regimen</NAME>
<IPD_DATA CI_END="0.974326674975792" CI_START="0.39725399369781106" EFFECT_SIZE="0.6221375754609606" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="-0.011295407235458329" LOG_CI_START="-0.40093172802315474" LOG_EFFECT_SIZE="-0.20611356762930652" ORDER="19948" O_E="-9.06" SE="0.22887430356158697" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="19.09" WEIGHT="10.670765790944662"/>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19949" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="21.66014533258804"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19950" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="8.580212409167133"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.875651804523069" CI_END="0.7109530872839482" CI_START="0.5480542962929645" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6242122186794447" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="529" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.14815905553731026" LOG_CI_START="-0.26117641339098163" LOG_EFFECT_SIZE="-0.20466773446414596" NO="5" P_CHI2="0.5598580046324828" P_Q="0.6855343112092265" P_Z="1.258837887928144E-12" Q="0.16396267038992285" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="978" TOTAL_2="935" WEIGHT="100.0" Z="7.098757146075014">
<NAME>Disease control_untreated vs treated patients</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.677337772797241" CI_END="0.7212134709592156" CI_START="0.5178635333409713" DF="4.0" EFFECT_SIZE="0.6111384101527619" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="338" I2="14.481267030500664" ID="CMP-002.05.01" LOG_CI_END="-0.1419361700408505" LOG_CI_START="-0.2857846698401616" LOG_EFFECT_SIZE="-0.213860419940506" NO="1" P_CHI2="0.3220346594651886" P_Z="5.616948413129863E-9" STUDIES="5" TAU2="0.0" TOTAL_1="678" TOTAL_2="642" WEIGHT="61.727633318642575" Z="5.82778021858815">
<NAME>Untreated patients</NAME>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19951" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="17.078007933010138"/>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19952" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="9.78845306302336"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19953" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="6.941383869546056"/>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19954" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="21.154693697664168"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19955" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="6.765094755398854"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.034351361335904884" CI_END="0.7970785381347192" CI_START="0.5233789883850013" DF="1.0" EFFECT_SIZE="0.6458902065772053" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="191" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-0.0984988843779582" LOG_CI_START="-0.28118371656739966" LOG_EFFECT_SIZE="-0.18984130047267897" NO="2" P_CHI2="0.8529614792431194" P_Z="4.631450930699587E-5" STUDIES="2" TAU2="0.0" TOTAL_1="300" TOTAL_2="293" WEIGHT="38.272366681357425" Z="4.073486640848802">
<NAME>Treated patients</NAME>
<IPD_DATA CI_END="0.974326674975792" CI_START="0.39725399369781106" EFFECT_SIZE="0.6221375754609606" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="-0.011295407235458329" LOG_CI_START="-0.40093172802315474" LOG_EFFECT_SIZE="-0.20611356762930652" ORDER="19956" O_E="-9.06" SE="0.22887430356158697" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="19.09" WEIGHT="8.413397972675186"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19957" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="29.858968708682237"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.875651804523068" CI_END="0.7109530872839482" CI_START="0.5480542962929645" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6242122186794447" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="529" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-0.14815905553731026" LOG_CI_START="-0.26117641339098163" LOG_EFFECT_SIZE="-0.20466773446414596" NO="6" P_CHI2="0.5598580046324828" P_Q="0.9767503470262914" P_Z="1.258837887928144E-12" Q="8.493287291928553E-4" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="978" TOTAL_2="935" WEIGHT="100.0" Z="7.098757146075014">
<NAME>Disease control_Anthracylin vs no-Anthracylin treatment</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.874802475793875" CI_END="0.7234475770860522" CI_START="0.5396695666730221" DF="5.0" EFFECT_SIZE="0.6248380913778204" ESTIMABLE="YES" EVENTS_1="303" EVENTS_2="414" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-0.14059293352505509" LOG_CI_START="-0.26787207220463266" LOG_EFFECT_SIZE="-0.20423250286484396" NO="1" P_CHI2="0.43135003795596394" P_Z="3.176119306511264E-10" STUDIES="6" TAU2="0.0" TOTAL_1="816" TOTAL_2="776" WEIGHT="78.84530630233583" Z="6.289928644084946">
<NAME>Anthracyclin based regimen</NAME>
<IPD_DATA CI_END="0.974326674975792" CI_START="0.39725399369781106" EFFECT_SIZE="0.6221375754609606" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="-0.011295407235458329" LOG_CI_START="-0.40093172802315474" LOG_EFFECT_SIZE="-0.20611356762930652" ORDER="19958" O_E="-9.06" SE="0.22887430356158697" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="19.09" WEIGHT="8.413397972675186"/>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19959" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="17.078007933010138"/>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19960" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="9.78845306302336"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19961" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="6.941383869546056"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19962" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="6.765094755398854"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19963" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="29.858968708682237"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.8252213987895776" CI_START="0.4686512298660301" DF="0.0" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" NO="2" P_CHI2="1.0" P_Z="9.986863792082828E-4" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="159" WEIGHT="21.154693697664168" Z="3.2908965343808667">
<NAME>No anthracylin based regimen</NAME>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19964" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="21.154693697664168"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.875651804523067" CI_END="0.7109530872839482" CI_START="0.5480542962929645" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6242122186794447" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="529" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.14815905553731026" LOG_CI_START="-0.26117641339098163" LOG_EFFECT_SIZE="-0.20466773446414596" NO="7" P_CHI2="0.559858004632483" P_Q="0.4663705423887745" P_Z="1.258837887928144E-12" Q="0.5305625063535784" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="978" TOTAL_2="935" WEIGHT="100.0" Z="7.098757146075014">
<NAME>Disease control_Full text vs abstract publication</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.52597686645327" CI_END="0.7052363759831777" CI_START="0.5233937284757946" DF="4.0" EFFECT_SIZE="0.6075494187986625" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="403" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="-0.15166529495278572" LOG_CI_START="-0.28117148556444826" LOG_EFFECT_SIZE="-0.21641839025861698" NO="1" P_CHI2="0.8220303664319772" P_Z="5.730266651497454E-11" STUDIES="5" TAU2="0.0" TOTAL_1="747" TOTAL_2="717" WEIGHT="76.15689731159101" Z="6.550609642606926">
<NAME>Full -Text</NAME>
<IPD_DATA CI_END="0.974326674975792" CI_START="0.39725399369781106" EFFECT_SIZE="0.6221375754609606" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="-0.011295407235458329" LOG_CI_START="-0.40093172802315474" LOG_EFFECT_SIZE="-0.20611356762930652" ORDER="19965" O_E="-9.06" SE="0.22887430356158697" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="19.09" WEIGHT="8.413397972675186"/>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19966" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="9.78845306302336"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19967" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="6.941383869546056"/>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19968" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="21.154693697664168"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19969" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="29.858968708682237"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.8191124317162193" CI_END="0.8883653537516408" CI_START="0.5213604775977492" DF="1.0" EFFECT_SIZE="0.680557554592739" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="126" I2="64.52784256670387" ID="CMP-002.07.02" LOG_CI_END="-0.051408387277871816" LOG_CI_START="-0.2828618941722467" LOG_EFFECT_SIZE="-0.1671351407250592" NO="2" P_CHI2="0.09314800222310637" P_Z="0.004645738631443408" STUDIES="2" TAU2="0.0" TOTAL_1="231" TOTAL_2="218" WEIGHT="23.84310268840899" Z="2.830623400505591">
<NAME>Abstract form</NAME>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19970" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="17.078007933010138"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19971" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="6.765094755398854"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.8756518045230495" CI_END="0.7109530872839481" CI_START="0.5480542962929645" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.6242122186794445" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="529" I2="0.0" I2_Q="69.88693502123262" ID="CMP-002.08" LOG_CI_END="-0.1481590555373103" LOG_CI_START="-0.26117641339098163" LOG_EFFECT_SIZE="-0.20466773446414602" NO="8" P_CHI2="0.5598580046324853" P_Q="0.0684078672578724" P_Z="1.2588378879281305E-12" Q="3.320817727139687" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="978" TOTAL_2="935" WEIGHT="100.0" Z="7.098757146075016">
<NAME>FFS_Sensitivity: Alloc. concealment</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>R + Chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Chemotherapy</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.5548340773833624" CI_END="0.6913572773900146" CI_START="0.5280277238223835" DF="5.0" EFFECT_SIZE="0.6041984852085361" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="502" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="-0.16029746130943215" LOG_CI_START="-0.27734327446052875" LOG_EFFECT_SIZE="-0.2188203678849804" NO="1" P_CHI2="0.906656591382746" P_Z="2.3289375128381013E-13" STUDIES="6" TAU2="0.0" TOTAL_1="928" TOTAL_2="894" WEIGHT="93.23490524460115" Z="7.32841318441212">
<NAME>Allocation concealment adaequate</NAME>
<IPD_DATA CI_END="0.974326674975792" CI_START="0.39725399369781106" EFFECT_SIZE="0.6221375754609606" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="-0.011295407235458329" LOG_CI_START="-0.40093172802315474" LOG_EFFECT_SIZE="-0.20611356762930652" ORDER="19972" O_E="-9.06" SE="0.22887430356158697" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="66" TOTAL_2="62" VAR="19.09" WEIGHT="8.413397972675186"/>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19973" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="17.078007933010138"/>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19974" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="9.78845306302336"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19975" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="6.941383869546056"/>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19976" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="21.154693697664168"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19977" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="29.858968708682237"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.613019680126052" CI_START="0.5930908579414262" DF="0.0" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" NO="2" P_CHI2="1.0" P_Z="0.9308455782441853" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="41" WEIGHT="6.765094755398854" Z="0.08678101535132651">
<NAME>Not adaequate</NAME>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19978" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="6.765094755398854"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.875420788701495" CI_END="0.7153395982603882" CI_START="0.5450268541747776" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="0.6244031477391098" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="487" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.14548773353241196" LOG_CI_START="-0.26358209894794266" LOG_EFFECT_SIZE="-0.20453491624017733" MODIFIED="2008-08-19 16:13:35 +0200" MODIFIED_BY="Nicole Skoetz" NO="9" P_CHI2="0.43127270656346794" P_Q="0.6911944452779593" P_Z="1.1278435099192543E-11" Q="0.15779556371728898" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="912" TOTAL_2="873" WEIGHT="100.0" Z="6.789165054591903">
<NAME>FFS_Endpoints according to start of measurement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.717625224984206" CI_END="0.7356309083597183" CI_START="0.5441631453003676" DF="4.0" EFFECT_SIZE="0.6326952100918662" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="388" I2="15.211577663772747" ID="CMP-002.09.01" LOG_CI_END="-0.1333400316796531" LOG_CI_START="-0.2642708751521539" LOG_EFFECT_SIZE="-0.19880545341590353" NO="1" P_CHI2="0.317516840054342" P_Z="2.648522775585179E-9" STUDIES="5" TAU2="0.0" TOTAL_1="731" TOTAL_2="696" WEIGHT="81.353159135749" Z="5.952020445162174">
<NAME>Start of treatment</NAME>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19979" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="10.687647370193927"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19980" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="7.5790385448245985"/>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19981" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="23.098022231846397"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19982" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="7.386555026225879"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19983" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="32.6018959626582"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.8076229804058744" CI_START="0.4302571093338341" DF="0.0" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" NO="2" P_CHI2="1.0" P_Z="0.0010019223547125511" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="177" WEIGHT="18.646840864250997" Z="3.2899863711846353">
<NAME>End of treatment</NAME>
<IPD_DATA CI_END="0.8076229804058744" CI_START="0.4302571093338341" EFFECT_SIZE="0.5894790318416825" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="99" LOG_CI_END="-0.09279133197521514" LOG_CI_START="-0.3662719448959383" LOG_EFFECT_SIZE="-0.22953163843557667" ORDER="19984" O_E="-20.48" SE="0.16064386578049977" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="38.75" WEIGHT="18.646840864250997"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="8.173917588916023" CI_END="0.6880379560511306" CI_START="0.5228210821878274" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.5997672454952445" ESTIMABLE="YES" EVENTS_1="339" EVENTS_2="477" I2="26.5957855002587" I2_Q="42.71454393188706" ID="CMP-002.10" LOG_CI_END="-0.16238760297251997" LOG_CI_START="-0.28164690828882105" LOG_EFFECT_SIZE="-0.22201725563067057" MODIFIED="2008-08-19 16:13:35 +0200" MODIFIED_BY="Nicole Skoetz" NO="10" P_CHI2="0.22563668020171945" P_Q="0.15524762243975843" P_Z="2.9322091212842017E-13" Q="5.236931336346475" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="898" TOTAL_2="852" WEIGHT="400.0" Z="7.297473749799858">
<NAME>FFS_Endpoints TTP, EFS, TTF, PFS</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>R + Chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Chemotherapy</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="2.3851299975062292" CI_END="0.8877872719274392" CI_START="0.5425248054945002" DF="1.0" EFFECT_SIZE="0.6940076491098113" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="142" I2="58.0735640805512" ID="CMP-002.10.01" LOG_CI_END="-0.051691085680671704" LOG_CI_START="-0.2655804000728009" LOG_EFFECT_SIZE="-0.15863574287673635" NO="1" P_CHI2="0.12249488277636322" P_Z="0.0036456184914548263" STUDIES="2" TAU2="0.0" TOTAL_1="212" TOTAL_2="200" WEIGHT="100.0" Z="2.907301316877764">
<NAME>Time to progression</NAME>
<IPD_DATA CI_END="0.8252213987895776" CI_START="0.4686512298660301" EFFECT_SIZE="0.62188505646502" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="115" LOG_CI_END="-0.08342951887661412" LOG_CI_START="-0.3291502389314751" LOG_EFFECT_SIZE="-0.20628987890404465" ORDER="19985" O_E="-22.8" SE="0.14433756729740643" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="48.0" WEIGHT="75.76953433307024"/>
<IPD_DATA CI_END="1.613019680126052" CI_START="0.5930908579414262" EFFECT_SIZE="0.978093669319235" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20763966616019983" LOG_CI_START="-0.22687877024451328" LOG_EFFECT_SIZE="-0.00961955204215671" ORDER="19986" O_E="-0.34" SE="0.25523828044507796" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="15.35" WEIGHT="24.230465666929753"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.5019758294691652" CI_END="0.7792189708783098" CI_START="0.5074074185165491" DF="1.0" EFFECT_SIZE="0.6287936755983518" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="185" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="-0.10834048265989106" LOG_CI_START="-0.2946431874941681" LOG_EFFECT_SIZE="-0.2014918350770296" NO="2" P_CHI2="0.4786332979070089" P_Z="2.2400125430017307E-5" STUDIES="2" TAU2="0.0" TOTAL_1="296" TOTAL_2="291" WEIGHT="100.0" Z="4.239516976215187">
<NAME>Progression free survival</NAME>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19987" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="18.862275449101794"/>
<IPD_DATA CI_END="0.8282422462340868" CI_START="0.5144345555507612" EFFECT_SIZE="0.6527453039507803" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="149" LOG_CI_END="-0.08184262116711609" LOG_CI_START="-0.2886698667149202" LOG_EFFECT_SIZE="-0.1852562439410181" ORDER="19988" O_E="-28.9" SE="0.1214913478461574" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="67.75" WEIGHT="81.1377245508982"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.049880425594152955" CI_END="0.7049047421014905" CI_START="0.3730943898436153" DF="1.0" EFFECT_SIZE="0.51283136083144" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="97" I2="0.0" ID="CMP-002.10.03" LOG_CI_END="-0.15186956779560568" LOG_CI_START="-0.42818128132175115" LOG_EFFECT_SIZE="-0.29002542455867847" NO="3" P_CHI2="0.8232714739809541" P_Z="3.88054695801556E-5" STUDIES="2" TAU2="0.0" TOTAL_1="285" TOTAL_2="265" WEIGHT="100.0" Z="4.114479111159077">
<NAME>Time to treatment failure</NAME>
<IPD_DATA CI_END="0.7539354292882832" CI_START="0.32817127884166325" EFFECT_SIZE="0.4974132627841504" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="61" LOG_CI_END="-0.1226658476376715" LOG_CI_START="-0.48389943055408313" LOG_EFFECT_SIZE="-0.3032826390958773" ORDER="19989" O_E="-15.51" SE="0.21219039474017432" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="223" TOTAL_2="205" VAR="22.21" WEIGHT="58.50895679662803"/>
<IPD_DATA CI_END="0.8773077800259893" CI_START="0.32672827795513243" EFFECT_SIZE="0.5353888868892701" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-0.05684801927089752" LOG_CI_START="-0.48581327621202286" LOG_EFFECT_SIZE="-0.27133064774146015" ORDER="19990" O_E="-9.84" SE="0.25197631533948484" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="15.75" WEIGHT="41.491043203371966"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.6418893906100427" CI_START="0.26090979294026756" DF="0.0" EFFECT_SIZE="0.4092373736532634" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="53" I2="0.0" ID="CMP-002.10.04" LOG_CI_END="-0.19253980243940594" LOG_CI_START="-0.583509619864506" LOG_EFFECT_SIZE="-0.388024711151956" NO="4" P_CHI2="1.0" P_Z="1.0007917692769114E-4" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="96" WEIGHT="100.0" Z="3.8903998471190766">
<NAME>Event free survival</NAME>
<IPD_DATA CI_END="0.6418893906100427" CI_START="0.26090979294026756" EFFECT_SIZE="0.4092373736532634" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="53" LOG_CI_END="-0.19253980243940594" LOG_CI_START="-0.583509619864506" LOG_EFFECT_SIZE="-0.388024711151956" ORDER="19991" O_E="-16.94" SE="0.22965760608731267" STUDY_ID="STD-Herold-2004" TOTAL_1="105" TOTAL_2="96" VAR="18.96" WEIGHT="100.0"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Overall Response</NAME>
<DICH_OUTCOME CHI2="32.09182909799098" CI_END="1.2652202545864428" CI_START="1.155069068157038" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.208890723133639" ESTIMABLE="YES" EVENTS_1="854" EVENTS_2="673" I2="81.30365214871591" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.10216613580827177" LOG_CI_START="0.0626079539447393" LOG_EFFECT_SIZE="0.08238704487650551" METHOD="MH" NO="1" P_CHI2="1.5669427503750555E-5" P_Q="0.0" P_Z="3.2422532723932274E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="100.0" Z="8.163956640256806">
<NAME>Overall Response Total Group</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R + Chemo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6898014709951208" CI_START="1.0264352435052722" EFFECT_SIZE="1.3169934640522876" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.22783568383499414" LOG_CI_START="0.011331555484064693" LOG_EFFECT_SIZE="0.11958361965952945" ORDER="19992" O_E="0.0" SE="0.12717559670605566" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.016173632397541313" WEIGHT="5.462751353778779"/>
<DICH_DATA CI_END="1.4767616332990867" CI_START="1.1561825227415" EFFECT_SIZE="1.3066774623737856" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="116" LOG_CI_END="0.1693104007302244" LOG_CI_START="0.0630264001417659" LOG_EFFECT_SIZE="0.11616840043599515" ORDER="19993" O_E="0.0" SE="0.06243174805994853" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.003897723165820887" WEIGHT="17.01362709167682"/>
<DICH_DATA CI_END="1.1248513298296345" CI_START="1.014356781452514" EFFECT_SIZE="1.0681762843925007" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.051095126090696504" LOG_CI_START="0.006190737011888931" LOG_EFFECT_SIZE="0.02864293155129273" ORDER="19994" O_E="0.0" SE="0.02637706042520241" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="6.957493166747791E-4" WEIGHT="27.902312601368678"/>
<DICH_DATA CI_END="1.506003342680305" CI_START="1.080547393600883" EFFECT_SIZE="1.2756598240469208" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="0.17782593581288902" LOG_CI_START="0.03364382011139015" LOG_EFFECT_SIZE="0.1057348779621396" ORDER="19995" O_E="0.0" SE="0.0846932884760438" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.007172953112886373" WEIGHT="6.486761156997033"/>
<DICH_DATA CI_END="1.6687039637969365" CI_START="1.2230451631227572" EFFECT_SIZE="1.4286008230452676" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" LOG_CI_END="0.22237929755824273" LOG_CI_START="0.08744249443027714" LOG_EFFECT_SIZE="0.15491089599425995" ORDER="19996" O_E="0.0" SE="0.079262546105315" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.006282551215097186" WEIGHT="13.17637249296558"/>
<DICH_DATA CI_END="1.2333108935754062" CI_START="0.9012475063157942" EFFECT_SIZE="1.0542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.09107256754865649" LOG_CI_START="-0.04515592393108705" LOG_EFFECT_SIZE="0.022958321808784727" ORDER="19997" O_E="0.0" SE="0.08002129023710983" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.006403406891211768" WEIGHT="5.578790189725059"/>
<DICH_DATA CI_END="1.2951654732435725" CI_START="1.0684155422720916" EFFECT_SIZE="1.1763396284354368" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.11232525839845234" LOG_CI_START="0.028740197089797328" LOG_EFFECT_SIZE="0.07053272774412483" ORDER="19998" O_E="0.0" SE="0.049098278765430346" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.0024106409777279085" WEIGHT="24.379385113488052"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.602432520283795" CI_END="1.2449122887885693" CI_START="1.1377957977080417" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1901495581223118" ESTIMABLE="YES" EVENTS_1="822" EVENTS_2="654" I2="69.927562098315" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.09513875397230834" LOG_CI_START="0.05606432542790401" LOG_EFFECT_SIZE="0.07560153970010615" METHOD="MH" NO="2" P_CHI2="8.278294486300242E-4" P_Q="0.0" P_Z="3.3426038612665505E-14" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="938" TOTAL_2="892" WEIGHT="100.0" Z="7.584310276967716">
<NAME>Overall Response FL vs MCL</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.703480322703008" CI_END="1.2422772325199425" CI_START="1.1315060810780657" DF="5.0" EFFECT_SIZE="1.1855986854670282" ESTIMABLE="YES" EVENTS_1="719" EVENTS_2="570" I2="79.75993692109489" ID="CMP-003.02.01" LOG_CI_END="0.09421852588728795" LOG_CI_START="0.05365689233542367" LOG_EFFECT_SIZE="0.07393770911135582" NO="1" P_CHI2="1.5895421998102233E-4" P_Z="8.97116913592432E-13" STUDIES="6" TAU2="0.0" TOTAL_1="808" TOTAL_2="762" WEIGHT="87.48225696571825" Z="7.145434454574422">
<NAME>follicular</NAME>
<DICH_DATA CI_END="1.7261380556052779" CI_START="1.0510422727090363" EFFECT_SIZE="1.346938775510204" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" LOG_CI_END="0.23707552741038895" LOG_CI_START="0.021620183616321093" LOG_EFFECT_SIZE="0.12934785551335498" ORDER="19999" O_E="0.0" SE="0.12655953546578788" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="35" TOTAL_2="30" VAR="0.01601731601731602" WEIGHT="3.367080425731973"/>
<DICH_DATA CI_END="1.39979007847963" CI_START="1.083875582523051" EFFECT_SIZE="1.2317460317460318" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="72" LOG_CI_END="0.14606291096849564" LOG_CI_START="0.034979432640717824" LOG_EFFECT_SIZE="0.09052117180460675" ORDER="20000" O_E="0.0" SE="0.06525098504182263" STUDY_ID="STD-Herold-2004" TOTAL_1="105" TOTAL_2="96" VAR="0.004257691048928159" WEIGHT="11.199670499236413"/>
<DICH_DATA CI_END="1.1248513298296345" CI_START="1.014356781452514" EFFECT_SIZE="1.0681762843925007" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.051095126090696504" LOG_CI_START="0.006190737011888931" LOG_EFFECT_SIZE="0.02864293155129273" ORDER="20001" O_E="0.0" SE="0.02637706042520241" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="6.957493166747791E-4" WEIGHT="28.640219058811795"/>
<DICH_DATA CI_END="1.6687039637969365" CI_START="1.2230451631227572" EFFECT_SIZE="1.4286008230452676" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" LOG_CI_END="0.22237929755824273" LOG_CI_START="0.08744249443027714" LOG_EFFECT_SIZE="0.15491089599425995" ORDER="20002" O_E="0.0" SE="0.079262546105315" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.006282551215097186" WEIGHT="13.524835736394307"/>
<DICH_DATA CI_END="1.2333108935754062" CI_START="0.9012475063157942" EFFECT_SIZE="1.0542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.09107256754865649" LOG_CI_START="-0.04515592393108705" LOG_EFFECT_SIZE="0.022958321808784727" ORDER="20003" O_E="0.0" SE="0.08002129023710983" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.006403406891211768" WEIGHT="5.726327254646212"/>
<DICH_DATA CI_END="1.2951654732435725" CI_START="1.0684155422720916" EFFECT_SIZE="1.1763396284354368" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.11232525839845234" LOG_CI_START="0.028740197089797328" LOG_EFFECT_SIZE="0.07053272774412483" ORDER="20004" O_E="0.0" SE="0.049098278765430346" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.0024106409777279085" WEIGHT="25.024123990897554"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6369757211112592" CI_END="1.4194732867529654" CI_START="1.0519195707224955" DF="2.0" EFFECT_SIZE="1.2219540623334533" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="84" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.1521272238960821" LOG_CI_START="0.021982535134512073" LOG_EFFECT_SIZE="0.08705487951529708" NO="2" P_CHI2="0.7272479562292531" P_Z="0.008739674305351598" STUDIES="3" TAU2="0.0" TOTAL_1="130" TOTAL_2="130" WEIGHT="12.51774303428175" Z="2.6220728660090975">
<NAME>Mantle cell</NAME>
<DICH_DATA CI_END="2.2079467798637644" CI_START="0.7336384760341683" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3439886009910153" LOG_CI_START="-0.1345178999509894" LOG_EFFECT_SIZE="0.10473535052001297" ORDER="20005" O_E="0.0" SE="0.2810770872987142" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="24" TOTAL_2="24" VAR="0.07900432900432902" WEIGHT="1.6377295948288166"/>
<DICH_DATA CI_END="1.497295169169942" CI_START="0.8341233501873526" EFFECT_SIZE="1.1175548589341693" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.17530742339282307" LOG_CI_START="-0.0787697211314166" LOG_EFFECT_SIZE="0.048268851130703234" ORDER="20006" O_E="0.0" SE="0.14924617239568774" STUDY_ID="STD-Herold-2004" TOTAL_1="44" TOTAL_2="46" VAR="0.02227441997476335" WEIGHT="4.221702955558728"/>
<DICH_DATA CI_END="1.506003342680305" CI_START="1.080547393600883" EFFECT_SIZE="1.2756598240469208" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="0.17782593581288902" LOG_CI_START="0.03364382011139015" LOG_EFFECT_SIZE="0.1057348779621396" ORDER="20007" O_E="0.0" SE="0.0846932884760438" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.007172953112886373" WEIGHT="6.658310483894206"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.824131422447073" CI_END="3.5130435882870272" CI_START="2.1659857403338267" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.7584782611796816" ESTIMABLE="YES" EVENTS_1="854" EVENTS_2="673" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.545683538358804" LOG_CI_START="0.3356555931412323" LOG_EFFECT_SIZE="0.44066956575001814" METHOD="MH" NO="3" P_CHI2="0.7004620914637563" P_Q="0.0" P_Z="1.958657624450979E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="100.0" Z="8.224586276442619">
<NAME>Sensitivity: attrition bias</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.761281380320785" CI_END="3.7377991150357275" CI_START="2.2170959694545838" DF="4.0" EFFECT_SIZE="2.8787252999507644" ESTIMABLE="YES" EVENTS_1="757" EVENTS_2="602" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.5726159568673592" LOG_CI_START="0.3457844924390182" LOG_EFFECT_SIZE="0.45920022465318866" NO="1" P_CHI2="0.5985347891060286" P_Z="2.0956918505314276E-15" STUDIES="5" TAU2="0.0" TOTAL_1="861" TOTAL_2="832" WEIGHT="84.48335165990635" Z="7.935547251181975">
<NAME>Less than 10% excluded from analysis</NAME>
<DICH_DATA CI_END="5.2640493550964464" CI_START="1.8669833266864553" EFFECT_SIZE="3.134946949602122" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="116" LOG_CI_END="0.7213199525180487" LOG_CI_START="0.2711404394485955" LOG_EFFECT_SIZE="0.4962301959833221" ORDER="20008" O_E="0.0" SE="0.26443767440152605" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.06992728364288751" WEIGHT="20.57356406043773"/>
<DICH_DATA CI_END="6.72009098484348" CI_START="1.2444829591224429" EFFECT_SIZE="2.891891891891892" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.8273751531056055" LOG_CI_START="0.09498895413082382" LOG_EFFECT_SIZE="0.4611820536182146" ORDER="20009" O_E="0.0" SE="0.4302072786479409" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.18507830260166708" WEIGHT="8.464378258796431"/>
<DICH_DATA CI_END="16.880517319363626" CI_START="1.6469668770559978" EFFECT_SIZE="5.2727272727272725" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="1.2273857518573124" LOG_CI_START="0.21668486495211223" LOG_EFFECT_SIZE="0.7220353084047122" ORDER="20010" O_E="0.0" SE="0.5936907040181929" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.3524686520376175" WEIGHT="3.5230114914990556"/>
<DICH_DATA CI_END="5.3500330480230245" CI_START="1.9618956375866956" EFFECT_SIZE="3.239784946236559" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" LOG_CI_END="0.7283564647370617" LOG_CI_START="0.2926759015017823" LOG_EFFECT_SIZE="0.510516183119422" ORDER="20011" O_E="0.0" SE="0.2559209194979732" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.06549551703668809" WEIGHT="21.22562042403796"/>
<DICH_DATA CI_END="3.4534483543315924" CI_START="1.3748145008001198" EFFECT_SIZE="2.178956372968349" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.5382529655987122" LOG_CI_START="0.13824410419275765" LOG_EFFECT_SIZE="0.3382485348957349" ORDER="20012" O_E="0.0" SE="0.23496718526565594" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.05520957815166508" WEIGHT="30.69677742513516"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3113765998963637" CI_END="4.014518575070187" CI_START="1.1024608514453917" DF="1.0" EFFECT_SIZE="2.103770321687997" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="71" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.6036334717251565" LOG_CI_START="0.04236317654975449" LOG_EFFECT_SIZE="0.32299832413745544" NO="2" P_CHI2="0.5768367846052402" P_Z="0.024081302664200714" STUDIES="2" TAU2="0.0" TOTAL_1="118" TOTAL_2="103" WEIGHT="15.516648340093653" Z="2.2558296343773865">
<NAME>More than 10% excluded from analysis</NAME>
<DICH_DATA CI_END="4.9886712379046765" CI_START="1.104392712558843" EFFECT_SIZE="2.3472222222222223" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.6979848841218906" LOG_CI_START="0.043123532242919566" LOG_EFFECT_SIZE="0.3705542081824051" ORDER="20013" O_E="0.0" SE="0.38466879970967943" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.14797008547008547" WEIGHT="10.820326203261434"/>
<DICH_DATA CI_END="5.4739015736045715" CI_START="0.43486499186316285" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.7382969840816469" LOG_CI_START="-0.3616455531362611" LOG_EFFECT_SIZE="0.1883257154726929" ORDER="20014" O_E="0.0" SE="0.6461116911651711" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.4174603174603174" WEIGHT="4.69632213683222"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.271984796439939" CI_END="3.4644289405165014" CI_START="1.994713205540733" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.628791006775882" ESTIMABLE="YES" EVENTS_1="723" EVENTS_2="583" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.5396316578737681" LOG_CI_START="0.29988046282746106" LOG_EFFECT_SIZE="0.4197560603506146" METHOD="MH" NO="4" P_CHI2="0.658133511813882" P_Q="0.0" P_Z="6.742712009967432E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="817" TOTAL_2="776" WEIGHT="100.00000000000001" Z="6.86300446110997">
<NAME>Overall Response_Doxorubicin vs Mitoxantrone</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R+ Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.035456160413858" CI_END="3.7621221293235294" CI_START="1.763404474640368" DF="2.0" EFFECT_SIZE="2.575683015627634" ESTIMABLE="YES" EVENTS_1="471" EVENTS_2="396" I2="1.74192699913758" ID="CMP-003.04.01" LOG_CI_END="0.5754328898933503" LOG_CI_START="0.24635193848027498" LOG_EFFECT_SIZE="0.41089241418681266" NO="1" P_CHI2="0.3614152450124227" P_Z="9.858346624415552E-7" STUDIES="3" TAU2="0.0" TOTAL_1="518" TOTAL_2="496" WEIGHT="54.18534224604126" Z="4.89444515015991">
<NAME>Doxorubicin based regimen</NAME>
<DICH_DATA CI_END="6.72009098484348" CI_START="1.2444829591224429" EFFECT_SIZE="2.891891891891892" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.8273751531056055" LOG_CI_START="0.09498895413082382" LOG_EFFECT_SIZE="0.4611820536182146" ORDER="20015" O_E="0.0" SE="0.4302072786479409" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.18507830260166708" WEIGHT="10.745090350897962"/>
<DICH_DATA CI_END="16.880517319363626" CI_START="1.6469668770559978" EFFECT_SIZE="5.2727272727272725" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="1.2273857518573124" LOG_CI_START="0.21668486495211223" LOG_EFFECT_SIZE="0.7220353084047122" ORDER="20016" O_E="0.0" SE="0.5936907040181929" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.3524686520376175" WEIGHT="4.472280848752125"/>
<DICH_DATA CI_END="3.4534483543315924" CI_START="1.3748145008001198" EFFECT_SIZE="2.178956372968349" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.5382529655987122" LOG_CI_START="0.13824410419275765" LOG_EFFECT_SIZE="0.3382485348957349" ORDER="20017" O_E="0.0" SE="0.23496718526565594" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.05520957815166508" WEIGHT="38.96797104639117"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2009869477633426" CI_END="4.026630374077699" CI_START="1.7992022831241175" DF="2.0" EFFECT_SIZE="2.6916022295906794" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="187" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.6049417652255118" LOG_CI_START="0.25507999353227595" LOG_EFFECT_SIZE="0.43001087937889393" NO="2" P_CHI2="0.548541125032705" P_Z="1.4505077799949783E-6" STUDIES="3" TAU2="0.0" TOTAL_1="299" TOTAL_2="280" WEIGHT="45.814657753958755" Z="4.817936137829968">
<NAME>Mitoxantrone based regimen</NAME>
<DICH_DATA CI_END="4.9886712379046765" CI_START="1.104392712558843" EFFECT_SIZE="2.3472222222222223" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.6979848841218906" LOG_CI_START="0.043123532242919566" LOG_EFFECT_SIZE="0.3705542081824051" ORDER="20018" O_E="0.0" SE="0.38466879970967943" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.14797008547008547" WEIGHT="13.735844397006527"/>
<DICH_DATA CI_END="5.2640493550964464" CI_START="1.8669833266864553" EFFECT_SIZE="3.134946949602122" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="116" LOG_CI_END="0.7213199525180487" LOG_CI_START="0.2711404394485955" LOG_EFFECT_SIZE="0.4962301959833221" ORDER="20019" O_E="0.0" SE="0.26443767440152605" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.06992728364288751" WEIGHT="26.11707533741814"/>
<DICH_DATA CI_END="5.4739015736045715" CI_START="0.43486499186316285" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.7382969840816469" LOG_CI_START="-0.3616455531362611" LOG_EFFECT_SIZE="0.1883257154726929" ORDER="20020" O_E="0.0" SE="0.6461116911651711" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.4174603174603174" WEIGHT="5.961738019534083"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.09182909799098" CI_END="1.2652202545864428" CI_START="1.155069068157038" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.208890723133639" ESTIMABLE="YES" EVENTS_1="854" EVENTS_2="673" I2="81.30365214871591" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.10216613580827177" LOG_CI_START="0.0626079539447393" LOG_EFFECT_SIZE="0.08238704487650551" METHOD="MH" NO="5" P_CHI2="1.5669427503750555E-5" P_Q="0.0" P_Z="3.2422532723932274E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="100.0" Z="8.163956640256806">
<NAME>Overall Response_untreated vs treated patients</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="32.035881883660245" CI_END="1.2765262568623064" CI_START="1.1503266947382418" DF="4.0" EFFECT_SIZE="1.2117847291507666" ESTIMABLE="YES" EVENTS_1="603" EVENTS_2="470" I2="87.51400066173866" ID="CMP-003.05.01" LOG_CI_END="0.10602975223320656" LOG_CI_START="0.060821198243048595" LOG_EFFECT_SIZE="0.0834254752381276" NO="1" P_CHI2="1.8810733066754182E-6" P_Z="4.702594337913397E-13" STUDIES="5" TAU2="0.0" TOTAL_1="677" TOTAL_2="642" WEIGHT="70.15786353273317" Z="7.233627817225256">
<NAME>Untreated patients</NAME>
<DICH_DATA CI_END="1.4767616332990867" CI_START="1.1561825227415" EFFECT_SIZE="1.3066774623737856" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="116" LOG_CI_END="0.1693104007302244" LOG_CI_START="0.0630264001417659" LOG_EFFECT_SIZE="0.11616840043599515" ORDER="20021" O_E="0.0" SE="0.06243174805994853" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.003897723165820887" WEIGHT="17.01362709167682"/>
<DICH_DATA CI_END="1.1248513298296345" CI_START="1.014356781452514" EFFECT_SIZE="1.0681762843925007" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.051095126090696504" LOG_CI_START="0.006190737011888931" LOG_EFFECT_SIZE="0.02864293155129273" ORDER="20022" O_E="0.0" SE="0.02637706042520241" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="6.957493166747791E-4" WEIGHT="27.902312601368678"/>
<DICH_DATA CI_END="1.506003342680305" CI_START="1.080547393600883" EFFECT_SIZE="1.2756598240469208" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="0.17782593581288902" LOG_CI_START="0.03364382011139015" LOG_EFFECT_SIZE="0.1057348779621396" ORDER="20023" O_E="0.0" SE="0.0846932884760438" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.007172953112886373" WEIGHT="6.486761156997033"/>
<DICH_DATA CI_END="1.6687039637969365" CI_START="1.2230451631227572" EFFECT_SIZE="1.4286008230452676" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" LOG_CI_END="0.22237929755824273" LOG_CI_START="0.08744249443027714" LOG_EFFECT_SIZE="0.15491089599425995" ORDER="20024" O_E="0.0" SE="0.079262546105315" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.006282551215097186" WEIGHT="13.17637249296558"/>
<DICH_DATA CI_END="1.2333108935754062" CI_START="0.9012475063157942" EFFECT_SIZE="1.0542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.09107256754865649" LOG_CI_START="-0.04515592393108705" LOG_EFFECT_SIZE="0.022958321808784727" ORDER="20025" O_E="0.0" SE="0.08002129023710983" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.006403406891211768" WEIGHT="5.578790189725059"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7097679526297295" CI_END="1.3169549613123608" CI_START="1.0972381187061186" DF="1.0" EFFECT_SIZE="1.202087011896836" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="203" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.11957092273097267" LOG_CI_START="0.040300886843684366" LOG_EFFECT_SIZE="0.07993590478732854" NO="2" P_CHI2="0.3995213247442677" P_Z="7.722410986793684E-5" STUDIES="2" TAU2="0.0" TOTAL_1="302" TOTAL_2="293" WEIGHT="29.84213646726683" Z="3.9528553936206947">
<NAME>Treated patients</NAME>
<DICH_DATA CI_END="1.6898014709951208" CI_START="1.0264352435052722" EFFECT_SIZE="1.3169934640522876" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.22783568383499414" LOG_CI_START="0.011331555484064693" LOG_EFFECT_SIZE="0.11958361965952945" ORDER="20026" O_E="0.0" SE="0.12717559670605566" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.016173632397541313" WEIGHT="5.462751353778779"/>
<DICH_DATA CI_END="1.2951654732435725" CI_START="1.0684155422720916" EFFECT_SIZE="1.1763396284354368" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.11232525839845234" LOG_CI_START="0.028740197089797328" LOG_EFFECT_SIZE="0.07053272774412483" ORDER="20027" O_E="0.0" SE="0.049098278765430346" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.0024106409777279085" WEIGHT="24.379385113488052"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.824131422447073" CI_END="3.5130435882870272" CI_START="2.1659857403338267" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.7584782611796816" ESTIMABLE="YES" EVENTS_1="854" EVENTS_2="673" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.545683538358804" LOG_CI_START="0.3356555931412323" LOG_EFFECT_SIZE="0.44066956575001814" METHOD="MH" NO="6" P_CHI2="0.7004620914637563" P_Q="0.0" P_Z="1.958657624450979E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="99.99999999999999" Z="8.224586276442619">
<NAME>Overall response_Anthracyclin vs no-Anthracyclin treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.271984796439939" CI_END="3.4644289405165014" CI_START="1.994713205540733" DF="5.0" EFFECT_SIZE="2.628791006775882" ESTIMABLE="YES" EVENTS_1="723" EVENTS_2="583" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.5396316578737681" LOG_CI_START="0.29988046282746106" LOG_EFFECT_SIZE="0.4197560603506146" NO="1" P_CHI2="0.658133511813882" P_Z="6.742712009967432E-12" STUDIES="6" TAU2="0.0" TOTAL_1="817" TOTAL_2="776" WEIGHT="78.77437957596203" Z="6.86300446110997">
<NAME>Anthracyclin based regimen</NAME>
<DICH_DATA CI_END="4.9886712379046765" CI_START="1.104392712558843" EFFECT_SIZE="2.3472222222222223" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.6979848841218906" LOG_CI_START="0.043123532242919566" LOG_EFFECT_SIZE="0.3705542081824051" ORDER="20028" O_E="0.0" SE="0.38466879970967943" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.14797008547008547" WEIGHT="10.820326203261434"/>
<DICH_DATA CI_END="5.2640493550964464" CI_START="1.8669833266864553" EFFECT_SIZE="3.134946949602122" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="116" LOG_CI_END="0.7213199525180487" LOG_CI_START="0.2711404394485955" LOG_EFFECT_SIZE="0.4962301959833221" ORDER="20029" O_E="0.0" SE="0.26443767440152605" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.06992728364288751" WEIGHT="20.57356406043773"/>
<DICH_DATA CI_END="6.72009098484348" CI_START="1.2444829591224429" EFFECT_SIZE="2.891891891891892" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.8273751531056055" LOG_CI_START="0.09498895413082382" LOG_EFFECT_SIZE="0.4611820536182146" ORDER="20030" O_E="0.0" SE="0.4302072786479409" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.18507830260166708" WEIGHT="8.464378258796431"/>
<DICH_DATA CI_END="16.880517319363626" CI_START="1.6469668770559978" EFFECT_SIZE="5.2727272727272725" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="1.2273857518573124" LOG_CI_START="0.21668486495211223" LOG_EFFECT_SIZE="0.7220353084047122" ORDER="20031" O_E="0.0" SE="0.5936907040181929" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.3524686520376175" WEIGHT="3.5230114914990556"/>
<DICH_DATA CI_END="5.4739015736045715" CI_START="0.43486499186316285" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.7382969840816469" LOG_CI_START="-0.3616455531362611" LOG_EFFECT_SIZE="0.1883257154726929" ORDER="20032" O_E="0.0" SE="0.6461116911651711" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.4174603174603174" WEIGHT="4.69632213683222"/>
<DICH_DATA CI_END="3.4534483543315924" CI_START="1.3748145008001198" EFFECT_SIZE="2.178956372968349" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.5382529655987122" LOG_CI_START="0.13824410419275765" LOG_EFFECT_SIZE="0.3382485348957349" ORDER="20033" O_E="0.0" SE="0.23496718526565594" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.05520957815166508" WEIGHT="30.69677742513516"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.3500330480230245" CI_START="1.9618956375866956" DF="0.0" EFFECT_SIZE="3.239784946236559" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.7283564647370617" LOG_CI_START="0.2926759015017823" LOG_EFFECT_SIZE="0.510516183119422" NO="2" P_CHI2="1.0" P_Z="4.364105415202055E-6" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="159" WEIGHT="21.22562042403796" Z="4.593242925544854">
<NAME>No Anthracyclin based regimen</NAME>
<DICH_DATA CI_END="5.3500330480230245" CI_START="1.9618956375866956" EFFECT_SIZE="3.239784946236559" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" LOG_CI_END="0.7283564647370617" LOG_CI_START="0.2926759015017823" LOG_EFFECT_SIZE="0.510516183119422" ORDER="20034" O_E="0.0" SE="0.2559209194979732" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.06549551703668809" WEIGHT="21.22562042403796"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.09182909799104" CI_END="1.2652202545864428" CI_START="1.1550690681570381" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2088907231336392" ESTIMABLE="YES" EVENTS_1="854" EVENTS_2="673" I2="81.30365214871594" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.10216613580827177" LOG_CI_START="0.06260795394473938" LOG_EFFECT_SIZE="0.08238704487650558" METHOD="MH" NO="7" P_CHI2="1.56694275029734E-5" P_Q="0.0" P_Z="3.242253272393088E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="100.00000000000003" Z="8.163956640256812">
<NAME>Overall Response_Full text vs Abstract publication</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="25.202380352308882" CI_END="1.2611217024356534" CI_START="1.1390644865147967" DF="4.0" EFFECT_SIZE="1.1985403390864797" ESTIMABLE="YES" EVENTS_1="654" EVENTS_2="522" I2="84.12848332545086" ID="CMP-003.07.01" LOG_CI_END="0.10075699945637223" LOG_CI_START="0.056548311739113205" LOG_EFFECT_SIZE="0.07865265559774272" NO="1" P_CHI2="4.580905488216214E-5" P_Z="3.079868691446547E-12" STUDIES="5" TAU2="0.0" TOTAL_1="748" TOTAL_2="717" WEIGHT="77.40758271859815" Z="6.974030681296427">
<NAME>Full Text</NAME>
<DICH_DATA CI_END="1.6898014709951208" CI_START="1.0264352435052722" EFFECT_SIZE="1.3169934640522876" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.22783568383499414" LOG_CI_START="0.011331555484064693" LOG_EFFECT_SIZE="0.11958361965952945" ORDER="20035" O_E="0.0" SE="0.12717559670605566" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.016173632397541313" WEIGHT="5.4627513537787795"/>
<DICH_DATA CI_END="1.1248513298296345" CI_START="1.014356781452514" EFFECT_SIZE="1.0681762843925007" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.051095126090696504" LOG_CI_START="0.006190737011888931" LOG_EFFECT_SIZE="0.02864293155129273" ORDER="20036" O_E="0.0" SE="0.02637706042520241" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="6.957493166747791E-4" WEIGHT="27.902312601368685"/>
<DICH_DATA CI_END="1.506003342680305" CI_START="1.080547393600883" EFFECT_SIZE="1.2756598240469208" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="0.17782593581288902" LOG_CI_START="0.03364382011139015" LOG_EFFECT_SIZE="0.1057348779621396" ORDER="20037" O_E="0.0" SE="0.0846932884760438" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.007172953112886373" WEIGHT="6.4867611569970345"/>
<DICH_DATA CI_END="1.6687039637969365" CI_START="1.2230451631227572" EFFECT_SIZE="1.4286008230452676" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" LOG_CI_END="0.22237929755824273" LOG_CI_START="0.08744249443027714" LOG_EFFECT_SIZE="0.15491089599425995" ORDER="20038" O_E="0.0" SE="0.079262546105315" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.006282551215097186" WEIGHT="13.176372492965582"/>
<DICH_DATA CI_END="1.2951654732435725" CI_START="1.0684155422720916" EFFECT_SIZE="1.1763396284354368" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.11232525839845234" LOG_CI_START="0.028740197089797328" LOG_EFFECT_SIZE="0.07053272774412483" ORDER="20039" O_E="0.0" SE="0.049098278765430346" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.0024106409777279085" WEIGHT="24.37938511348806"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.903300390555176" CI_END="1.3765070060278297" CI_START="1.124888247348586" DF="1.0" EFFECT_SIZE="1.244353869875324" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="151" I2="79.60557338224234" ID="CMP-003.07.02" LOG_CI_END="0.13877842616994718" LOG_CI_START="0.05110937936243536" LOG_EFFECT_SIZE="0.09494390276619127" NO="2" P_CHI2="0.026805553635234847" P_Z="2.183916168014206E-5" STUDIES="2" TAU2="0.0" TOTAL_1="231" TOTAL_2="218" WEIGHT="22.592417281401886" Z="4.245207099878337">
<NAME>Abstract form</NAME>
<DICH_DATA CI_END="1.4767616332990867" CI_START="1.1561825227415" EFFECT_SIZE="1.3066774623737856" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="116" LOG_CI_END="0.1693104007302244" LOG_CI_START="0.0630264001417659" LOG_EFFECT_SIZE="0.11616840043599515" ORDER="20040" O_E="0.0" SE="0.06243174805994853" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.003897723165820887" WEIGHT="17.013627091676824"/>
<DICH_DATA CI_END="1.2333108935754062" CI_START="0.9012475063157942" EFFECT_SIZE="1.0542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.09107256754865649" LOG_CI_START="-0.04515592393108705" LOG_EFFECT_SIZE="0.022958321808784727" ORDER="20041" O_E="0.0" SE="0.08002129023710983" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.006403406891211768" WEIGHT="5.57879018972506"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.09182909799098" CI_END="1.2652202545864428" CI_START="1.155069068157038" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.208890723133639" ESTIMABLE="YES" EVENTS_1="854" EVENTS_2="673" I2="81.30365214871591" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.10216613580827177" LOG_CI_START="0.0626079539447393" LOG_EFFECT_SIZE="0.08238704487650551" METHOD="MH" NO="8" P_CHI2="1.5669427503750555E-5" P_Q="0.0" P_Z="3.2422532723932274E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="100.0" Z="8.163956640256806">
<NAME>Overall Response Allocation concealment</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="31.26267648308803" CI_END="1.2769877896965873" CI_START="1.161785515875851" DF="5.0" EFFECT_SIZE="1.218025417641115" ESTIMABLE="YES" EVENTS_1="809" EVENTS_2="638" I2="84.00648772761086" ID="CMP-003.08.01" LOG_CI_END="0.10618674464575914" LOG_CI_START="0.0651259577707794" LOG_EFFECT_SIZE="0.08565635120826927" NO="1" P_CHI2="8.312505240137824E-6" P_Z="2.90253893564182E-16" STUDIES="6" TAU2="0.0" TOTAL_1="929" TOTAL_2="894" WEIGHT="94.42120981027495" Z="8.177308629105738">
<NAME>Adaequate</NAME>
<DICH_DATA CI_END="1.6898014709951208" CI_START="1.0264352435052722" EFFECT_SIZE="1.3169934640522876" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.22783568383499414" LOG_CI_START="0.011331555484064693" LOG_EFFECT_SIZE="0.11958361965952945" ORDER="20042" O_E="0.0" SE="0.12717559670605566" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.016173632397541313" WEIGHT="5.462751353778779"/>
<DICH_DATA CI_END="1.4767616332990867" CI_START="1.1561825227415" EFFECT_SIZE="1.3066774623737856" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="116" LOG_CI_END="0.1693104007302244" LOG_CI_START="0.0630264001417659" LOG_EFFECT_SIZE="0.11616840043599515" ORDER="20043" O_E="0.0" SE="0.06243174805994853" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.003897723165820887" WEIGHT="17.01362709167682"/>
<DICH_DATA CI_END="1.1248513298296345" CI_START="1.014356781452514" EFFECT_SIZE="1.0681762843925007" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="185" LOG_CI_END="0.051095126090696504" LOG_CI_START="0.006190737011888931" LOG_EFFECT_SIZE="0.02864293155129273" ORDER="20044" O_E="0.0" SE="0.02637706042520241" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="6.957493166747791E-4" WEIGHT="27.902312601368678"/>
<DICH_DATA CI_END="1.506003342680305" CI_START="1.080547393600883" EFFECT_SIZE="1.2756598240469208" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="44" LOG_CI_END="0.17782593581288902" LOG_CI_START="0.03364382011139015" LOG_EFFECT_SIZE="0.1057348779621396" ORDER="20045" O_E="0.0" SE="0.0846932884760438" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.007172953112886373" WEIGHT="6.486761156997033"/>
<DICH_DATA CI_END="1.6687039637969365" CI_START="1.2230451631227572" EFFECT_SIZE="1.4286008230452676" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="90" LOG_CI_END="0.22237929755824273" LOG_CI_START="0.08744249443027714" LOG_EFFECT_SIZE="0.15491089599425995" ORDER="20046" O_E="0.0" SE="0.079262546105315" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.006282551215097186" WEIGHT="13.17637249296558"/>
<DICH_DATA CI_END="1.2951654732435725" CI_START="1.0684155422720916" EFFECT_SIZE="1.1763396284354368" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="167" LOG_CI_END="0.11232525839845234" LOG_CI_START="0.028740197089797328" LOG_EFFECT_SIZE="0.07053272774412483" ORDER="20047" O_E="0.0" SE="0.049098278765430346" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.0024106409777279085" WEIGHT="24.379385113488052"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2333108935754062" CI_START="0.9012475063157942" DF="0.0" EFFECT_SIZE="1.0542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.09107256754865649" LOG_CI_START="-0.04515592393108705" LOG_EFFECT_SIZE="0.022958321808784727" NO="2" P_CHI2="1.0" P_Z="0.508857448251947" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="41" WEIGHT="5.578790189725059" Z="0.6606178105905169">
<NAME>Not adaequate</NAME>
<DICH_DATA CI_END="1.2333108935754062" CI_START="0.9012475063157942" EFFECT_SIZE="1.0542857142857143" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.09107256754865649" LOG_CI_START="-0.04515592393108705" LOG_EFFECT_SIZE="0.022958321808784727" ORDER="20048" O_E="0.0" SE="0.08002129023710983" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.006403406891211768" WEIGHT="5.578790189725059"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-08-19 16:15:52 +0200" MODIFIED_BY="Nicole Skoetz" NO="4">
<NAME>Complete Response</NAME>
<DICH_OUTCOME CHI2="37.844368950660886" CI_END="2.401484183119536" CI_START="1.70809821294255" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0253322793053683" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="146" I2="84.14559373992357" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.38047973059333295" LOG_CI_START="0.23251283831594155" LOG_EFFECT_SIZE="0.3064962844546373" METHOD="MH" NO="1" P_CHI2="1.2048638005079937E-6" P_Q="0.0" P_Z="4.6742638516087E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="100.00000000000001" Z="8.119676904483041">
<NAME>Complete Response Total Group</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>R + Chemo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.215224083572533" CI_START="1.2054743326234414" EFFECT_SIZE="2.5073529411764706" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7172729735810079" LOG_CI_START="0.08115796766355252" LOG_EFFECT_SIZE="0.3992154706222802" ORDER="20049" O_E="0.0" SE="0.3736571032959761" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.1396196308435398" WEIGHT="5.541677681818107"/>
<DICH_DATA CI_END="4.4419946221604825" CI_START="1.9895667842106148" EFFECT_SIZE="2.9728176795580112" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="25" LOG_CI_END="0.6475780284205954" LOG_CI_START="0.29875852178215623" LOG_EFFECT_SIZE="0.4731682751013759" ORDER="20050" O_E="0.0" SE="0.20489830488382468" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.04198331534426478" WEIGHT="16.738682510729035"/>
<DICH_DATA CI_END="1.7340263825705347" CI_START="0.7771687632221554" EFFECT_SIZE="1.1608751608751608" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.23905570082049024" LOG_CI_START="-0.10948466333843533" LOG_EFFECT_SIZE="0.06478551874102745" ORDER="20051" O_E="0.0" SE="0.2047343352095808" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.04191614801370899" WEIGHT="24.09788119233223"/>
<DICH_DATA CI_END="13.930143969459788" CI_START="1.8530286055574625" EFFECT_SIZE="5.080645161290323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="1.1439556049249575" LOG_CI_START="0.26788212365773584" LOG_EFFECT_SIZE="0.7059188642913466" ORDER="20052" O_E="0.0" SE="0.5146098995300387" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.26482334869431645" WEIGHT="2.692015556620898"/>
<DICH_DATA CI_END="7.245460199811738" CI_START="2.2168071439957875" EFFECT_SIZE="4.007716049382716" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="12" LOG_CI_END="0.8600659751614363" LOG_CI_START="0.34572791235598244" LOG_EFFECT_SIZE="0.6028969437587094" ORDER="20053" O_E="0.0" SE="0.3021247241063961" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.09127934891636598" WEIGHT="8.020047552163916"/>
<DICH_DATA CI_END="1.4133391921028597" CI_START="0.7664123359547672" EFFECT_SIZE="1.0407692307692307" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.1502464021744869" LOG_CI_START="-0.11553751359291455" LOG_EFFECT_SIZE="0.017354444290786163" ORDER="20054" O_E="0.0" SE="0.15612278777337324" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.02437432486212974" WEIGHT="18.918542506206773"/>
<DICH_DATA CI_END="2.710992967316793" CI_START="1.32055664204334" EFFECT_SIZE="1.892094017094017" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="36" LOG_CI_END="0.4331283909631962" LOG_CI_START="0.12075703394074273" LOG_EFFECT_SIZE="0.2769427124519695" ORDER="20055" O_E="0.0" SE="0.18348848137814425" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.033668022798457584" WEIGHT="23.991153000129053"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.587694277970876" CI_END="2.7136279242377186" CI_START="1.8859279029302056" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.262234872971966" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="135" I2="64.26327723588943" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.43355029965089564" LOG_CI_START="0.2755250860905641" LOG_EFFECT_SIZE="0.3545376928707299" METHOD="MH" NO="2" P_CHI2="0.006532620429814839" P_Q="0.0" P_Z="1.4360964712682079E-18" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1041" TOTAL_2="1002" WEIGHT="100.0" Z="8.794559976003567">
<NAME>Complete Response FL vs MCL</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.48811346496348" CI_END="2.6283120251203207" CI_START="1.7718836397442768" DF="4.0" EFFECT_SIZE="2.1580229557291193" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="116" I2="75.74009902042569" ID="CMP-004.02.01" LOG_CI_END="0.41967692205362606" LOG_CI_START="0.24843519820777535" LOG_EFFECT_SIZE="0.33405606013070066" NO="1" P_CHI2="0.002429489283237052" P_Z="2.058135769067989E-14" STUDIES="5" TAU2="0.0" TOTAL_1="867" TOTAL_2="834" WEIGHT="85.99560046954812" Z="7.6469429525587564">
<NAME>Follicula lymphoma</NAME>
<DICH_DATA CI_END="5.215224083572533" CI_START="1.2054743326234414" EFFECT_SIZE="2.5073529411764706" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7172729735810079" LOG_CI_START="0.08115796766355252" LOG_EFFECT_SIZE="0.3992154706222802" ORDER="20056" O_E="0.0" SE="0.3736571032959761" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.1396196308435398" WEIGHT="6.079388857476435"/>
<DICH_DATA CI_END="4.4419946221604825" CI_START="1.9895667842106148" EFFECT_SIZE="2.9728176795580112" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="25" LOG_CI_END="0.6475780284205954" LOG_CI_START="0.29875852178215623" LOG_EFFECT_SIZE="0.4731682751013759" ORDER="20057" O_E="0.0" SE="0.20489830488382468" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.04198331534426478" WEIGHT="18.362843490236365"/>
<DICH_DATA CI_END="1.7340263825705347" CI_START="0.7771687632221554" EFFECT_SIZE="1.1608751608751608" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.23905570082049024" LOG_CI_START="-0.10948466333843533" LOG_EFFECT_SIZE="0.06478551874102745" ORDER="20058" O_E="0.0" SE="0.2047343352095808" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.04191614801370899" WEIGHT="26.43610812843086"/>
<DICH_DATA CI_END="7.245460199811738" CI_START="2.2168071439957875" EFFECT_SIZE="4.007716049382716" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="12" LOG_CI_END="0.8600659751614363" LOG_CI_START="0.34572791235598244" LOG_EFFECT_SIZE="0.6028969437587094" ORDER="20059" O_E="0.0" SE="0.3021247241063961" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.09127934891636598" WEIGHT="8.798235935847561"/>
<DICH_DATA CI_END="2.710992967316793" CI_START="1.32055664204334" EFFECT_SIZE="1.892094017094017" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="36" LOG_CI_END="0.4331283909631962" LOG_CI_START="0.12075703394074273" LOG_EFFECT_SIZE="0.2769427124519695" ORDER="20060" O_E="0.0" SE="0.18348848137814425" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.033668022798457584" WEIGHT="26.319024057556902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9702276610461213" CI_END="4.667366142861098" CI_START="1.804557880681788" DF="2.0" EFFECT_SIZE="2.9021599465100736" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="19" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.6690718715058732" LOG_CI_START="0.256370816491159" LOG_EFFECT_SIZE="0.46272134399851605" NO="2" P_CHI2="0.3733968177762461" P_Z="1.1075644300510932E-5" STUDIES="3" TAU2="0.0" TOTAL_1="174" TOTAL_2="168" WEIGHT="14.004399530451884" Z="4.395031987900908">
<NAME>Mantle cell lymphoma</NAME>
<DICH_DATA CI_END="5.215224083572533" CI_START="1.2054743326234414" EFFECT_SIZE="2.5073529411764706" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7172729735810079" LOG_CI_START="0.08115796766355252" LOG_EFFECT_SIZE="0.3992154706222802" ORDER="20061" O_E="0.0" SE="0.3736571032959761" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.1396196308435398" WEIGHT="6.079388857476435"/>
<DICH_DATA CI_END="4.689299541043512" CI_START="0.9323142589166737" EFFECT_SIZE="2.090909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6711079752995931" LOG_CI_START="-0.03043767358085746" LOG_EFFECT_SIZE="0.3203351508593678" ORDER="20062" O_E="0.0" SE="0.4120913868593457" STUDY_ID="STD-Herold-2004" TOTAL_1="44" TOTAL_2="46" VAR="0.16981931112365894" WEIGHT="4.971787782952542"/>
<DICH_DATA CI_END="13.930143969459788" CI_START="1.8530286055574625" EFFECT_SIZE="5.080645161290323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="1.1439556049249575" LOG_CI_START="0.26788212365773584" LOG_EFFECT_SIZE="0.7059188642913466" ORDER="20063" O_E="0.0" SE="0.5146098995300387" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.26482334869431645" WEIGHT="2.9532228900229067"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.69120603882036" CI_END="2.213707426254055" CI_START="1.550199199722506" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8524814386651232" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="134" I2="82.57305742660382" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.3451202219809743" LOG_CI_START="0.19038750835204227" LOG_EFFECT_SIZE="0.26775386516650823" METHOD="MH" MODIFIED="2008-08-19 16:15:52 +0200" MODIFIED_BY="Nicole Skoetz" NO="3" P_CHI2="2.6656511693423646E-5" P_Q="0.0" P_Z="1.1757997429289665E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="817" TOTAL_2="776" WEIGHT="100.0" Z="6.7831542553600634">
<NAME>Complete Response_Doxorubicine vs Mitoxantrone</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.9818464853078" CI_END="2.5913736033416606" CI_START="1.5793065031679396" DF="2.0" EFFECT_SIZE="2.0230109203598534" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="59" I2="90.90158326173028" ID="CMP-004.03.01" LOG_CI_END="0.4135300305747537" LOG_CI_START="0.19846642368581185" LOG_EFFECT_SIZE="0.30599822713028274" NO="1" P_CHI2="1.685415021834835E-5" P_Z="2.4417104752063087E-8" STUDIES="3" TAU2="0.0" TOTAL_1="299" TOTAL_2="280" WEIGHT="44.791176340429985" Z="5.577377903999987">
<NAME>Mitixantrone based regimen</NAME>
<DICH_DATA CI_END="5.215224083572533" CI_START="1.2054743326234414" EFFECT_SIZE="2.5073529411764706" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7172729735810079" LOG_CI_START="0.08115796766355252" LOG_EFFECT_SIZE="0.3992154706222802" ORDER="20064" O_E="0.0" SE="0.3736571032959761" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.1396196308435398" WEIGHT="6.024875567272028"/>
<DICH_DATA CI_END="4.4419946221604825" CI_START="1.9895667842106148" EFFECT_SIZE="2.9728176795580112" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="25" LOG_CI_END="0.6475780284205954" LOG_CI_START="0.29875852178215623" LOG_EFFECT_SIZE="0.4731682751013759" ORDER="20065" O_E="0.0" SE="0.20489830488382468" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.04198331534426478" WEIGHT="18.198185653794415"/>
<DICH_DATA CI_END="1.4133391921028597" CI_START="0.7664123359547672" EFFECT_SIZE="1.0407692307692307" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.1502464021744869" LOG_CI_START="-0.11553751359291455" LOG_EFFECT_SIZE="0.017354444290786163" ORDER="20066" O_E="0.0" SE="0.15612278777337324" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.02437432486212974" WEIGHT="20.56811511936354"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.37137333659192" CI_END="2.2114574458527585" CI_START="1.328645014925334" DF="2.0" EFFECT_SIZE="1.7141300741635037" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="75" I2="76.10905738419471" ID="CMP-004.03.02" LOG_CI_END="0.3446785868396315" LOG_CI_START="0.12340896239312396" LOG_EFFECT_SIZE="0.2340437746163777" NO="2" P_CHI2="0.015211778144452515" P_Z="3.379944306634317E-5" STUDIES="3" TAU2="0.0" TOTAL_1="518" TOTAL_2="496" WEIGHT="55.208823659570015" Z="4.146229923798747">
<NAME>Doxorubicine based regimen</NAME>
<DICH_DATA CI_END="1.7340263825705347" CI_START="0.7771687632221554" EFFECT_SIZE="1.1608751608751608" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.23905570082049024" LOG_CI_START="-0.10948466333843533" LOG_EFFECT_SIZE="0.06478551874102745" ORDER="20067" O_E="0.0" SE="0.2047343352095808" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.04191614801370899" WEIGHT="26.19905811105815"/>
<DICH_DATA CI_END="13.930143969459788" CI_START="1.8530286055574625" EFFECT_SIZE="5.080645161290323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="1.1439556049249575" LOG_CI_START="0.26788212365773584" LOG_EFFECT_SIZE="0.7059188642913466" ORDER="20068" O_E="0.0" SE="0.5146098995300387" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.26482334869431645" WEIGHT="2.92674162682091"/>
<DICH_DATA CI_END="2.710992967316793" CI_START="1.32055664204334" EFFECT_SIZE="1.892094017094017" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="36" LOG_CI_END="0.4331283909631962" LOG_CI_START="0.12075703394074273" LOG_EFFECT_SIZE="0.2769427124519695" ORDER="20069" O_E="0.0" SE="0.18348848137814425" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.033668022798457584" WEIGHT="26.083023921690952"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="37.8443689506609" CI_END="2.4014841831195364" CI_START="1.7080982129425502" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0253322793053687" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="146" I2="84.14559373992358" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.38047973059333307" LOG_CI_START="0.23251283831594163" LOG_EFFECT_SIZE="0.30649628445463734" METHOD="MH" MODIFIED="2008-08-19 16:15:52 +0200" MODIFIED_BY="Nicole Skoetz" NO="4" P_CHI2="1.2048638000639045E-6" P_Q="0.0" P_Z="4.674263851608566E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="100.00000000000003" Z="8.119676904483045">
<NAME>Complete Response_anthracycline vs no anthracyclin treatment</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="28.691206038820358" CI_END="2.213707426254055" CI_START="1.550199199722506" DF="5.0" EFFECT_SIZE="1.8524814386651232" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="134" I2="82.57305742660382" ID="CMP-004.04.01" LOG_CI_END="0.3451202219809743" LOG_CI_START="0.19038750835204227" LOG_EFFECT_SIZE="0.26775386516650823" NO="1" P_CHI2="2.6656511693423646E-5" P_Z="1.1757997429289792E-11" STUDIES="6" TAU2="0.0" TOTAL_1="817" TOTAL_2="776" WEIGHT="91.97995244783611" Z="6.783154255360062">
<NAME>Anthracyclin based regimen</NAME>
<DICH_DATA CI_END="5.215224083572533" CI_START="1.2054743326234414" EFFECT_SIZE="2.5073529411764706" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7172729735810079" LOG_CI_START="0.08115796766355252" LOG_EFFECT_SIZE="0.3992154706222802" ORDER="20070" O_E="0.0" SE="0.3736571032959761" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.1396196308435398" WEIGHT="5.541677681818108"/>
<DICH_DATA CI_END="4.4419946221604825" CI_START="1.9895667842106148" EFFECT_SIZE="2.9728176795580112" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="25" LOG_CI_END="0.6475780284205954" LOG_CI_START="0.29875852178215623" LOG_EFFECT_SIZE="0.4731682751013759" ORDER="20071" O_E="0.0" SE="0.20489830488382468" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.04198331534426478" WEIGHT="16.73868251072904"/>
<DICH_DATA CI_END="1.7340263825705347" CI_START="0.7771687632221554" EFFECT_SIZE="1.1608751608751608" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.23905570082049024" LOG_CI_START="-0.10948466333843533" LOG_EFFECT_SIZE="0.06478551874102745" ORDER="20072" O_E="0.0" SE="0.2047343352095808" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.04191614801370899" WEIGHT="24.097881192332235"/>
<DICH_DATA CI_END="13.930143969459788" CI_START="1.8530286055574625" EFFECT_SIZE="5.080645161290323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="1.1439556049249575" LOG_CI_START="0.26788212365773584" LOG_EFFECT_SIZE="0.7059188642913466" ORDER="20073" O_E="0.0" SE="0.5146098995300387" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.26482334869431645" WEIGHT="2.6920155566208983"/>
<DICH_DATA CI_END="1.4133391921028597" CI_START="0.7664123359547672" EFFECT_SIZE="1.0407692307692307" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.1502464021744869" LOG_CI_START="-0.11553751359291455" LOG_EFFECT_SIZE="0.017354444290786163" ORDER="20074" O_E="0.0" SE="0.15612278777337324" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.02437432486212974" WEIGHT="18.918542506206773"/>
<DICH_DATA CI_END="2.710992967316793" CI_START="1.32055664204334" EFFECT_SIZE="1.892094017094017" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="36" LOG_CI_END="0.4331283909631962" LOG_CI_START="0.12075703394074273" LOG_EFFECT_SIZE="0.2769427124519695" ORDER="20075" O_E="0.0" SE="0.18348848137814425" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.033668022798457584" WEIGHT="23.991153000129056"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.245460199811738" CI_START="2.2168071439957875" DF="0.0" EFFECT_SIZE="4.007716049382716" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="12" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.8600659751614363" LOG_CI_START="0.34572791235598244" LOG_EFFECT_SIZE="0.6028969437587094" NO="2" P_CHI2="1.0" P_Z="4.330350594212563E-6" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="159" WEIGHT="8.020047552163918" Z="4.594862335138113">
<NAME>No Anthracyclin based regimen</NAME>
<DICH_DATA CI_END="7.245460199811738" CI_START="2.2168071439957875" EFFECT_SIZE="4.007716049382716" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="12" LOG_CI_END="0.8600659751614363" LOG_CI_START="0.34572791235598244" LOG_EFFECT_SIZE="0.6028969437587094" ORDER="20076" O_E="0.0" SE="0.3021247241063961" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.09127934891636598" WEIGHT="8.020047552163918"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="37.84436895066088" CI_END="2.401484183119536" CI_START="1.70809821294255" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0253322793053683" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="146" I2="84.14559373992357" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.38047973059333295" LOG_CI_START="0.23251283831594155" LOG_EFFECT_SIZE="0.3064962844546373" METHOD="MH" MODIFIED="2008-08-19 16:15:52 +0200" MODIFIED_BY="Nicole Skoetz" NO="5" P_CHI2="1.2048638008410606E-6" P_Q="0.0" P_Z="4.674263851608633E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="979" TOTAL_2="935" WEIGHT="99.99999999999999" Z="8.119676904483043">
<NAME>Complete Response _untreated vs treated patients</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Chemo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>R + Chemo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="37.532419139463094" CI_END="2.4839847907752937" CI_START="1.663546551663393" DF="4.0" EFFECT_SIZE="2.032787331001095" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="102" I2="89.34254681229903" ID="CMP-004.05.01" LOG_CI_END="0.3951489323650153" LOG_CI_START="0.22103495840451698" LOG_EFFECT_SIZE="0.30809194538476614" NO="1" P_CHI2="1.3991529290713345E-7" P_Z="4.026418299163237E-12" STUDIES="5" TAU2="0.0" TOTAL_1="677" TOTAL_2="642" WEIGHT="70.46716931805284" Z="6.936251044594727">
<NAME>Complete remission untreated patients</NAME>
<DICH_DATA CI_END="4.4419946221604825" CI_START="1.9895667842106148" EFFECT_SIZE="2.9728176795580112" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="25" LOG_CI_END="0.6475780284205954" LOG_CI_START="0.29875852178215623" LOG_EFFECT_SIZE="0.4731682751013759" ORDER="20077" O_E="0.0" SE="0.20489830488382468" STUDY_ID="STD-Herold-2004" TOTAL_1="181" TOTAL_2="177" VAR="0.04198331534426478" WEIGHT="16.738682510729028"/>
<DICH_DATA CI_END="1.7340263825705347" CI_START="0.7771687632221554" EFFECT_SIZE="1.1608751608751608" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.23905570082049024" LOG_CI_START="-0.10948466333843533" LOG_EFFECT_SIZE="0.06478551874102745" ORDER="20078" O_E="0.0" SE="0.2047343352095808" STUDY_ID="STD-Hiddemann-2005" TOTAL_1="222" TOTAL_2="205" VAR="0.04191614801370899" WEIGHT="24.097881192332224"/>
<DICH_DATA CI_END="13.930143969459788" CI_START="1.8530286055574625" EFFECT_SIZE="5.080645161290323" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="1.1439556049249575" LOG_CI_START="0.26788212365773584" LOG_EFFECT_SIZE="0.7059188642913466" ORDER="20079" O_E="0.0" SE="0.5146098995300387" STUDY_ID="STD-Lenz-2005" TOTAL_1="62" TOTAL_2="60" VAR="0.26482334869431645" WEIGHT="2.692015556620897"/>
<DICH_DATA CI_END="7.245460199811738" CI_START="2.2168071439957875" EFFECT_SIZE="4.007716049382716" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="12" LOG_CI_END="0.8600659751614363" LOG_CI_START="0.34572791235598244" LOG_EFFECT_SIZE="0.6028969437587094" ORDER="20080" O_E="0.0" SE="0.3021247241063961" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.09127934891636598" WEIGHT="8.020047552163915"/>
<DICH_DATA CI_END="1.4133391921028597" CI_START="0.7664123359547672" EFFECT_SIZE="1.0407692307692307" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.1502464021744869" LOG_CI_START="-0.11553751359291455" LOG_EFFECT_SIZE="0.017354444290786163" ORDER="20081" O_E="0.0" SE="0.15612278777337324" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="50" TOTAL_2="41" VAR="0.02437432486212974" WEIGHT="18.918542506206766"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.45818391400711916" CI_END="2.7716614972739095" CI_START="1.4540856332972503" DF="1.0" EFFECT_SIZE="2.007544062666904" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="44" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.4427401888391795" LOG_CI_START="0.16258998353357737" LOG_EFFECT_SIZE="0.30266508618637844" NO="2" P_CHI2="0.4984739789369459" P_Z="2.285908560790714E-5" STUDIES="2" TAU2="0.0" TOTAL_1="302" TOTAL_2="293" WEIGHT="29.532830681947146" Z="4.234961510421932">
<NAME>Complete remission_treated patients</NAME>
<DICH_DATA CI_END="5.215224083572533" CI_START="1.2054743326234414" EFFECT_SIZE="2.5073529411764706" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7172729735810079" LOG_CI_START="0.08115796766355252" LOG_EFFECT_SIZE="0.3992154706222802" ORDER="20082" O_E="0.0" SE="0.3736571032959761" STUDY_ID="STD-Forstpointner-2004" TOTAL_1="68" TOTAL_2="62" VAR="0.1396196308435398" WEIGHT="5.541677681818105"/>
<DICH_DATA CI_END="2.710992967316793" CI_START="1.32055664204334" EFFECT_SIZE="1.892094017094017" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="36" LOG_CI_END="0.4331283909631962" LOG_CI_START="0.12075703394074273" LOG_EFFECT_SIZE="0.2769427124519695" ORDER="20083" O_E="0.0" SE="0.18348848137814425" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.033668022798457584" WEIGHT="23.991153000129042"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-08-19 16:16:12 +0200" MODIFIED_BY="Nicole Skoetz" NO="5">
<NAME>Toxicity Grade 3/4</NAME>
<DICH_OUTCOME CHI2="16.90014587019072" CI_END="1.375484834627459" CI_START="1.104979648532448" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2328352481691793" ESTIMABLE="YES" EVENTS_1="456" EVENTS_2="358" I2="17.160478332356497" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.13845580644949834" LOG_CI_START="0.043354279277735976" LOG_EFFECT_SIZE="0.09090504286361716" METHOD="MH" MODIFIED="2008-08-19 16:16:12 +0200" MODIFIED_BY="Nicole Skoetz" NO="1" P_CHI2="0.26153827901903925" P_Q="0.0" P_Z="1.789936015213177E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2346" TOTAL_2="2257" WEIGHT="500.0" Z="3.7469558128959726">
<NAME>Adverse events (number of patients)</NAME>
<GROUP_LABEL_1>R + Chemotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>R + Chemotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9998726829529856" CI_END="1.4817175644465252" CI_START="0.7448892125878565" DF="3.0" EFFECT_SIZE="1.050578616695661" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="56" I2="24.99761272938342" ID="CMP-005.01.01" LOG_CI_END="0.17076542908731918" LOG_CI_START="-0.12790831509010542" LOG_EFFECT_SIZE="0.02142855699860687" NO="1" P_CHI2="0.2614779568243233" P_Z="0.7785278777089831" STUDIES="4" TAU2="0.0" TOTAL_1="645" TOTAL_2="622" WEIGHT="100.0" Z="0.2812379780727155">
<NAME>Infection</NAME>
<DICH_DATA CI_END="1.3997948723984475" CI_START="0.2761906056981628" EFFECT_SIZE="0.6217798594847775" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.14606439831217383" LOG_CI_START="-0.5587910975272459" LOG_EFFECT_SIZE="-0.20636334960753597" ORDER="20084" O_E="0.0" SE="0.41403560734705086" STUDY_ID="STD-Herold-2004" TOTAL_1="183" TOTAL_2="177" VAR="0.1714254841512413" WEIGHT="25.06842471450342"/>
<DICH_DATA CI_END="2.7342307195838265" CI_START="0.35231331854749515" EFFECT_SIZE="0.9814814814814815" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.43683515837169395" LOG_CI_START="-0.4530709388160529" LOG_EFFECT_SIZE="-0.00811789022217945" ORDER="20085" O_E="0.0" SE="0.5227352465943083" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.2732521380320122" WEIGHT="12.443955274244075"/>
<DICH_DATA CI_END="9.594992157831639" CI_START="0.8041746419165176" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9820446241145505" LOG_CI_START="-0.09464962564912492" LOG_EFFECT_SIZE="0.44369749923271273" ORDER="20086" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="0.4" WEIGHT="5.764083178978858"/>
<DICH_DATA CI_END="1.6824985344916032" CI_START="0.692904979578557" EFFECT_SIZE="1.079727564102564" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.2259546946122183" LOG_CI_START="-0.1593263175874761" LOG_EFFECT_SIZE="0.033314188512371126" ORDER="20087" O_E="0.0" SE="0.22631597373786935" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.05121891996891997" WEIGHT="56.72353683227365"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6075267998118026" CI_END="9.775091221399812" CI_START="1.4724324966619202" DF="1.0" EFFECT_SIZE="3.7938320959451737" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" I2="37.79263897080455" ID="CMP-005.01.02" LOG_CI_END="0.9901208189339623" LOG_CI_START="0.16803539378224414" LOG_EFFECT_SIZE="0.5790781063581033" NO="2" P_CHI2="0.20483986021997636" P_Z="0.005758892821721148" STUDIES="2" TAU2="0.0" TOTAL_1="249" TOTAL_2="232" WEIGHT="99.99999999999999" Z="2.7612026633073445">
<NAME>Fever</NAME>
<DICH_DATA CI_END="29.36161192292177" CI_START="1.5612071768606914" EFFECT_SIZE="6.770491803278689" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4677798942281552" LOG_CI_START="0.19346053906311292" LOG_EFFECT_SIZE="0.830620216645634" ORDER="20088" O_E="0.0" SE="0.7485414972064877" STUDY_ID="STD-Herold-2004" TOTAL_1="183" TOTAL_2="177" VAR="0.5603143730401302" WEIGHT="38.32095945174186"/>
<DICH_DATA CI_END="7.165541129772503" CI_START="0.527645313739327" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8552489931702367" LOG_CI_START="-0.2776579146762976" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="20089" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="0.44285714285714284" WEIGHT="61.67904054825813"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.002592871506908628" CI_END="1.5489527786361397" CI_START="1.11227955495906" DF="1.0" EFFECT_SIZE="1.3125808574232694" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="110" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.19003817806240011" LOG_CI_START="0.04621395443815448" LOG_EFFECT_SIZE="0.1181260662502773" NO="3" P_CHI2="0.9593890902299537" P_Z="0.0012840320320299172" STUDIES="2" TAU2="0.0" TOTAL_1="345" TOTAL_2="336" WEIGHT="100.00000000000001" Z="3.2195249124488416">
<NAME>Leukocytopenia</NAME>
<DICH_DATA CI_END="1.5430654502964594" CI_START="1.1117425924225568" EFFECT_SIZE="1.3097677595628416" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="96" LOG_CI_END="0.1883843473850893" LOG_CI_START="0.04600424441220179" LOG_EFFECT_SIZE="0.11719429589864554" ORDER="20090" O_E="0.0" SE="0.0836347772791506" STUDY_ID="STD-Herold-2004" TOTAL_1="183" TOTAL_2="177" VAR="0.006994775970533124" WEIGHT="87.35278372591007"/>
<DICH_DATA CI_END="2.5636722799294187" CI_START="0.6920744919225857" EFFECT_SIZE="1.332010582010582" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.4088625075414489" LOG_CI_START="-0.15984715743662598" LOG_EFFECT_SIZE="0.12450767505241149" ORDER="20091" O_E="0.0" SE="0.33406287236636517" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.11159800269366638" WEIGHT="12.647216274089939"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2132613743762766" CI_END="1.7222632871394392" CI_START="0.7573086903779755" DF="3.0" EFFECT_SIZE="1.1420529560706176" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="0.23609954398831895" LOG_CI_START="-0.12072705946807791" LOG_EFFECT_SIZE="0.05768624226012056" NO="4" P_CHI2="0.7498255448650596" P_Z="0.5262676727672166" STUDIES="4" TAU2="0.0" TOTAL_1="645" TOTAL_2="622" WEIGHT="100.0" Z="0.6337137205472109">
<NAME>Thrombocytopenia</NAME>
<DICH_DATA CI_END="1.9627503973585072" CI_START="0.5884292603821816" EFFECT_SIZE="1.0746812386156648" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.29286507395443906" LOG_CI_START="-0.2303057395703345" LOG_EFFECT_SIZE="0.03127966719205225" ORDER="20092" O_E="0.0" SE="0.3073131256017457" STUDY_ID="STD-Herold-2004" TOTAL_1="183" TOTAL_2="177" VAR="0.09444135716711431" WEIGHT="46.79996759600757"/>
<DICH_DATA CI_END="101.43113668426645" CI_START="0.2374835174345737" EFFECT_SIZE="4.9079754601226995" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0061712924176853" LOG_CI_START="-0.6243665272417138" LOG_EFFECT_SIZE="0.6909023825879858" ORDER="20093" O_E="0.0" SE="1.5451909366401444" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="2.3876150306748465" WEIGHT="1.2905639950175496"/>
<DICH_DATA CI_END="8.758774641763413" CI_START="0.31714228204169503" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9424433523388599" LOG_CI_START="-0.49874585310614694" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="20094" O_E="0.0" SE="0.8465616732800196" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="0.7166666666666667" WEIGHT="5.5797278802989645"/>
<DICH_DATA CI_END="1.934154490604866" CI_START="0.5613881953945727" EFFECT_SIZE="1.042022792022792" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.28649116040755385" LOG_CI_START="-0.2507367237445052" LOG_EFFECT_SIZE="0.01787721833152436" ORDER="20095" O_E="0.0" SE="0.315570318471835" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.09958462590041536" WEIGHT="46.32974052867592"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7745289669191493" CI_END="1.3848913180136464" CI_START="0.9984866547390117" DF="2.0" EFFECT_SIZE="1.1759232540011046" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="149" I2="47.01325602403728" ID="CMP-005.01.05" LOG_CI_END="0.1414156926503145" LOG_CI_START="-6.577353119949902E-4" LOG_EFFECT_SIZE="0.07037897866915975" NO="5" P_CHI2="0.15148574219831168" P_Z="0.052159318419913406" STUDIES="3" TAU2="0.0" TOTAL_1="462" TOTAL_2="445" WEIGHT="100.0" Z="1.9418165020535696">
<NAME>Granulocytopenia</NAME>
<DICH_DATA CI_END="2.653556517896145" CI_START="1.0437810778663796" EFFECT_SIZE="1.6642512077294687" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="23" LOG_CI_END="0.4238283420686745" LOG_CI_START="0.018609419504779314" LOG_EFFECT_SIZE="0.2212188807867269" ORDER="20096" O_E="0.0" SE="0.2380276009800489" STUDY_ID="STD-Marcus-2005" TOTAL_1="162" TOTAL_2="159" VAR="0.05665713882831738" WEIGHT="15.361343133324889"/>
<DICH_DATA CI_END="1.5463505976201968" CI_START="0.38265318178296714" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.18930796652252718" LOG_CI_START="-0.4171946711362007" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="20097" O_E="0.0" SE="0.35626265159721265" STUDY_ID="STD-Rivas_x002d_Vera-2005" TOTAL_1="66" TOTAL_2="55" VAR="0.12692307692307692" WEIGHT="9.384114316405322"/>
<DICH_DATA CI_END="1.3428773507792124" CI_START="0.9457545287685972" EFFECT_SIZE="1.1269571136827774" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="113" LOG_CI_END="0.12803634899619556" LOG_CI_START="-0.024221570400534215" LOG_EFFECT_SIZE="0.05190738929783071" ORDER="20098" O_E="0.0" SE="0.08943705554249544" STUDY_ID="STD-van-Oers-2006" TOTAL_1="234" TOTAL_2="231" VAR="0.007998986904111414" WEIGHT="75.25454255026979"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-08-19 16:45:04 +0200" MODIFIED_BY="Nicole Skoetz">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-08-19 16:11:52 +0200" MODIFIED_BY="Nicole Skoetz" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Overall survival, outcome: 1.1 Overall survival Total group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA30AAADwCAMAAACDkv0QAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-08-19 16:31:56 +0200" MODIFIED_BY="Nicole Skoetz" NO="2" REF_ID="CMP-001.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Overall survival, outcome: 1.5 Overall survival untreated vs treated patients.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA30AAAGwCAMAAAAqvfzIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-08-19 16:32:30 +0200" MODIFIED_BY="Nicole Skoetz" NO="3" REF_ID="CMP-001.08" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Overall survival, outcome: 1.8 Overall survival_Alloc. concealment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0gAAAGwCAMAAACkZ7W0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-08-19 16:32:30 +0200" MODIFIED_BY="Nicole Skoetz" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Overall survival, outcome: 1.3 Sensitivity: attrition bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA30AAAGwCAMAAAAqvfzIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2008-08-19 16:32:39 +0200" MODIFIED_BY="Nicole Skoetz" NO="5" REF_ID="CMP-001.07" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Overall survival, outcome: 1.7 Overall survival_Full Text vs Abstract Publication.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA30AAAGwCAMAAAAqvfzIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2008-08-19 16:32:39 +0200" MODIFIED_BY="Nicole Skoetz" NO="6" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Overall survival, outcome: 1.2 Overall survival FL vs MCL.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA30AAAHACAMAAAAhn/EJAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2008-08-19 16:33:18 +0200" MODIFIED_BY="Nicole Skoetz" NO="7" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Disease Control, outcome: 2.1 FFS Total group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0gAAADwCAMAAAANSLRsAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2008-08-19 16:37:22 +0200" MODIFIED_BY="Nicole Skoetz" NO="8" REF_ID="CMP-002.09" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Disease Control, outcome: 2.9 FFS_Endpoints according to start of measurement.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0gAAAGgCAMAAACnsbcvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2008-08-19 16:37:22 +0200" MODIFIED_BY="Nicole Skoetz" NO="9" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Disease Control, outcome: 2.2 FFS_FL vs MCL.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0gAAAGQCAMAAACjy7CCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2008-08-19 16:39:22 +0200" MODIFIED_BY="Nicole Skoetz" NO="10" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Overall Response, outcome: 3.1 Overall Response Total Group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu4AAADwCAMAAABogBE6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2008-08-19 16:45:00 +0200" MODIFIED_BY="Nicole Skoetz" NO="11" REF_ID="CMP-003.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Overall Response, outcome: 3.2 Overall Response FL vs MCL.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu4AAAHACAMAAADKjR0jAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2008-08-19 16:45:00 +0200" MODIFIED_BY="Nicole Skoetz" NO="12" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Complete Response, outcome: 4.1 Complete Response Total Group.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtwAAADwCAMAAAAEhkM/AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2008-08-19 16:45:04 +0200" MODIFIED_BY="Nicole Skoetz" NO="13" REF_ID="CMP-004.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Complete Response, outcome: 4.2 Complete Response FL vs MCL.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtwAAAGwCAMAAACtqULnAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2008-08-19 16:45:04 +0200" MODIFIED_BY="Nicole Skoetz" NO="14" REF_ID="CMP-005.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Toxicity Grade 3/4, outcome: 5.1 Adverse events (number of patients).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuAAAAMgCAMAAABVnyc7AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-08-19 16:01:21 +0200" MODIFIED_BY="Nicole Skoetz">
<APPENDIX ID="APP-01" MODIFIED="2008-08-19 16:00:17 +0200" MODIFIED_BY="Nicole Skoetz" NO="1">
<TITLE MODIFIED="2008-08-19 16:00:14 +0200" MODIFIED_BY="Nicole Skoetz">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-19 16:00:17 +0200" MODIFIED_BY="Nicole Skoetz">
<P>#1 - #36 Randomised controlled trials search filter [<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>]</P>
<P>#37 IDEC*<BR/>#38 Ritux*<BR/>#39 anti-CD20*<BR/>#40 "Antigens, CD20" [MESH]<BR/>#41 Mabth*<BR/>#42 monocl* near antibo*<BR/>#43 "Antibodies, Monoclonal" [MESH]<BR/>#44 #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43</P>
<P>#45 lymphom*<BR/>#46 non-hodgkin*<BR/>#47 nonhodgkin*<BR/>#48 NHL*<BR/>#49 hematol* near malign* (note: the keywords haematol* near malig* did not indicate a hit)<BR/>#50 bcell*<BR/>#51 b-cell*<BR/>#52 "lymphoma" [MESH]<BR/>#53 #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52</P>
<P>#55 #36 AND #44 AND #53</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-08-19 16:00:52 +0200" MODIFIED_BY="Nicole Skoetz" NO="2">
<TITLE MODIFIED="2008-08-19 16:00:49 +0200" MODIFIED_BY="Nicole Skoetz">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-19 16:00:52 +0200" MODIFIED_BY="Nicole Skoetz">
<P>#1 Clinical trial<BR/>#2 Randomized controlled trial<BR/>#3 Randomization<BR/>#4 single blind procedure<BR/>#5 double blind procedure<BR/>#6 crossover procedure<BR/>#7 Placebo<BR/>#8 randomi?ed controlled trial?<BR/>#9 rct<BR/>#10 random allocation<BR/>#11 randomly allocated<BR/>#12 allocated randomly<BR/>#13 single blind?<BR/>#14 double blind?<BR/>#15 (treble or triple) blind?<BR/>#16 placebo?<BR/>#17 prospective study?<BR/>#18 #1 OR #2 OR #3 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17</P>
<P>#19 IDEC?<BR/>#20 Ritux?<BR/>#21 ?cd20?<BR/>#22 mabth?<BR/>#23 monocl? antibo?<BR/>#24 #19 OR #20 OR #21 OR #22 OR #23</P>
<P>#25 lymphom?<BR/>#26 non?hodgkin?<BR/>#27 nhl?<BR/>#28 h?ematol? malig?<BR/>#29 bcell?<BR/>#30 b?cell?<BR/>#31 #25 OR #26 OR #27 OR #28 OR #29 OR #30<BR/>#32 #18 AND #24 AND #31</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-08-19 16:01:21 +0200" MODIFIED_BY="Nicole Skoetz" NO="3">
<TITLE MODIFIED="2008-08-19 16:01:18 +0200" MODIFIED_BY="Nicole Skoetz">LILAC search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-19 16:01:21 +0200" MODIFIED_BY="Nicole Skoetz">
<P>#1 - #36 Randomised controlled trials search filter Castro 1999 (see at www.geocities.com/otavioclark/lilacs.htm the link for the article)<BR/>#37 IDEC$<BR/>#38 Ritux$<BR/>#39 anti-CD20$<BR/>#40 Antigen$<BR/>#41 Mabth$<BR/>#42 Anticorp$ Monoclo$<BR/>#43 #37 OR #38 OR #39 OR #40 OR #41 OR #42</P>
<P>#45 lymphom$ OR linfom$<BR/>#46 non-hodgkin$ OR N$o Hodgkin$ OR n$o-Hodgkin$<BR/>#47 nonhodgkin$<BR/>#48 NHL$<BR/>#49 hematol$ malign$ OR Neopl$ Hematol$<BR/>#50 bcel$ OR Celu$ B<BR/>#51 b-cell$<BR/>#52 #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51<BR/>#53 #36 AND #44 AND #52</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>